Podcasts about phase ii

Topics covered in this episode: * Free-threaded Python no longer “experimental” as of Python 3.14* typed-ffmpeg pyleak * Optimizing Test Execution: Running live_server Tests Last with pytest* Extras Joke Watch on YouTube About the show Sponsored by PropelAuth: pythonbytes.fm/propelauth66 Connect with the hosts Michael: @mkennedy@fosstodon.org / @mkennedy.codes (bsky) Brian: @brianokken@fosstodon.org / @brianokken.bsky.social Show: @pythonbytes@fosstodon.org / @pythonbytes.fm (bsky) Join us on YouTube at pythonbytes.fm/live to be part of the audience. Usually Monday at 10am PT. Older video versions available there too. Finally, if you want an artisanal, hand-crafted digest of every week of the show notes in email form? Add your name and email to our friends of the show list, we'll never share it. Brian #1: Free-threaded Python no longer “experimental” as of Python 3.14 “PEP 779 ("Criteria for supported status for free-threaded Python") has been accepted, which means free-threaded Python is now a supported build!” - Hugo van Kemenade PEP 779 – Criteria for supported status for free-threaded Python As noted in the discussion of PEP 779, “The Steering Council (SC) approves PEP 779, with the effect of removing the “experimental” tag from the free-threaded build of Python 3.14.” We are in Phase II then. “We are confident that the project is on the right path, and we appreciate the continued dedication from everyone working to make free-threading ready for broader adoption across the Python community.” “Keep in mind that any decision to transition to Phase III, with free-threading as the default or sole build of Python is still undecided, and dependent on many factors both within CPython itself and the community. We leave that decision for the future.” How long will all this take? According to Thomas Wouters, a few years, at least: “In other words: it'll be a few years at least. It can't happen before 3.16 (because we won't have Stable ABI support until 15) and may well take longer.” Michael #2: typed-ffmpeg typed-ffmpeg offers a modern, Pythonic interface to FFmpeg, providing extensive support for complex filters with detailed typing and documentation. Inspired by ffmpeg-python, this package enhances functionality by addressing common limitations, such as lack of IDE integration and comprehensive typing, while also introducing new features like JSON serialization of filter graphs and automatic FFmpeg validation. Features : Zero Dependencies: Built purely with the Python standard library, ensuring maximum compatibility and security. User-Friendly: Simplifies the construction of filter graphs with an intuitive Pythonic interface. Comprehensive FFmpeg Filter Support: Out-of-the-box support for most FFmpeg filters, with IDE auto-completion. Integrated Documentation: In-line docstrings provide immediate reference for filter usage, reducing the need to consult external documentation. Robust Typing: Offers static and dynamic type checking, enhancing code reliability and development experience. Filter Graph Serialization: Enables saving and reloading of filter graphs in JSON format for ease of use and repeatability. Graph Visualization: Leverages graphviz for visual representation, aiding in understanding and debugging. Validation and Auto-correction: Assists in identifying and fixing errors within filter graphs. Input and Output Options Support: Provide a more comprehensive interface for input and output options, including support for additional codecs and formats. Partial Evaluation: Enhance the flexibility of filter graphs by enabling partial evaluation, allowing for modular construction and reuse. Media File Analysis: Built-in support for analyzing media files using FFmpeg's ffprobe utility, providing detailed metadata extraction with both dictionary and dataclass interfaces. Michael #3: pyleak Detect leaked asyncio tasks, threads, and event loop blocking with stack trace in Python. Inspired by goleak. Use as context managers or function dectorators When using no_task_leaks, you get detailed stack trace information showing exactly where leaked tasks are executing and where they were created. Even has great examples and a pytest plugin. Brian #4: Optimizing Test Execution: Running live_server Tests Last with pytest Tim Kamanin “When working with Django applications, it's common to have a mix of fast unit tests and slower end-to-end (E2E) tests that use pytest's live_server fixture and browser automation tools like Playwright or Selenium. ” Tim is running E2E tests last for Faster feedback from quick tests To not tie up resources early in the test suite. He did this with custom “e2e” marker Implementing a pytest_collection_modifyitems hook function to look for tests using the live_server fixture, and for them automatically add the e2e marker to those tests move those tests to the end The reason for the marker is to be able to Just run e2e tests with -m e2e Avoid running them sometimes with -m "not e2e" Cool small writeup. The technique works for any system that has some tests that are slower or resource bound based on a particular fixture or set of fixtures. Extras Brian: Is Free-Threading Our Only Option? - Interesting discussion started by Eric Snow and recommended by John Hagen Free-threaded Python on GitHub Actions - How to add FT tests to your projects, by Hugo van Kemenade Michael: New course! LLM Building Blocks in Python Talk Python Deep Dives Complete: 600K Words of Talk Python Insights .folders on Linux Write up on XDG for Python devs. They keep pulling me back - ChatGPT Pro with o3-pro Python Bytes is the #1 Python news podcast and #17 of all tech news podcasts. Python 3.13.4, 3.12.11, 3.11.13, 3.10.18 and 3.9.23 are now available Python 3.13.5 is now available! Joke: Naming is hard

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world.Jefferies predicts an increase in small tuck-in deals in the biotech industry as companies face challenges accessing capital. Companies and industry groups are offering solutions to mitigate the impact of Trump tariffs on rare disease, cell, and gene therapy. Pitchbook suggests a shift towards more sustainable investing in biotech VC firms. Gilead is gearing up to challenge J&J in the $20 billion multiple myeloma CAR-T market. PTP's generative AI is revolutionizing data summaries for biotech QC workflows. Sanofi recently acquired Blueprint for $9.5 billion, while BMS has committed up to $11 billion with Biontech. Lilly has signed a deal worth up to $870 million, and Regeneron is investing nearly $2 billion in a Chinese obesity drug. Merck's CEO is emphasizing diversity in operations following the defeat of an anti-DEI measure. Immuno-oncology drugs Keytruda and Opdivo may face scrutiny in the near future.In other news, Vigil Neuroscience's Trem2 antibody for a rare brain disease failed in a Phase II trial shortly after Sanofi's acquisition of the company. Analysts believe the results were not surprising and should not impact the deal. Lilly has signed a deal worth up to $870 million to develop a long-acting GLP-1 obesity drug, while the FDA is committed to making rare disease drugs available at the first sign of promise. Pharma tuck-in deals are increasing after a slow first quarter for small biotechs. BioAgc Biologics will be attending Bio International in Boston to discuss their global drug production capabilities.Stay tuned for more updates on investing in research, welcoming global talent, the biotech VC cycle, Gilead's challenge to J&J in the multiple myeloma CAR-T market, and much more. Upcoming events and job listings in the pharmaceutical industry are also featured in our newsletter.Thank you for tuning in to Pharma and Biotech daily.

Faron Pharmaceuticals CEO Dr. Juho Jalkanen joined Steve Darling from Proactive to discuss the company's presentation of Phase II data from its BEXMAB study during a Rapid Oral Abstract Session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, which has recently concluded. The BEXMAB study is evaluating bexmarilimab, Faron's novel humanized anti-Clever-1 antibody, in combination with azacitidine, the current standard-of-care, in patients with high-risk myelodysplastic syndromes (MDS). The Phase II data presented focused on two patient populations: frontline treatment-naïve (n=21) and relapsed/refractory (r/r) MDS (n=32), with the majority (66% and 80% respectively) classified as very high/high risk at baseline. Jalkanen emphasized the unmet medical need in these populations, particularly for r/r MDS patients who have failed prior hypomethylating agent (HMA) therapies and have limited treatment options. In this context, the BEXMAB results are highly encouraging, showing an estimated median overall survival (mOS) of 13.4 months in r/r MDS patients — more than double the typical 5–6 months under current standard-of-care. These findings not only validate the therapeutic potential of bexmarilimab but also support progression to a confirmatory registrational Phase III trial, which would evaluate bexmarilimab + azacitidine versus placebo + azacitidine in frontline high-risk MDS patients. The company has received prior FDA guidance on trial design and is preparing for an end-of-Phase II meeting to discuss key parameters, including the proposed primary endpoint of composite complete response (cCR), a measure strongly correlated with overall survival. #proactiveinvestors #faronpharmaceuticalsltd #aim #farn #firstnorth #faron #MDS #Phase2Results #ASCO2025 #BiotechNews #CancerResearch #Immunotherapy #FDAUpdate #Hematology #ClinicalTrials (edited)

Zach catches up on the three newest series to be released in the DC Absolute Universe!On the docket:Absolute Martian Manhunter #1-3 (DC Comics)Written by Deniz CampArt by Javier RodriguezLetters by Hassan Otsmane-ElhaouAbsolute Flash #1-3 (DC Comics)Written by Jeff LemireArt by Nick RoblesColors by Adriano LucasLetters by Tom NapolitanoAbsolute Green Lantern #1-2 (DC Comics)Written by Al EwingArt by Jahnoy LindsayLetters by Lucas Gattoni---------------------------------------------------Check out Dreampass and all their killer tracks on Spotify!---------------------------------------------------Join the Patreon to help us keep the lights on, and internet connected! https://www.patreon.com/tctwl---------------------------------------------------Listen to my other podcast!TFD: NerdcastAnd I am also part of the team over at...I Read Comic Books!---------------------------------------------------Want to try out all the sweet gigs over on Fiverr.com? Click on the link below and sign up!https://go.fiverr.com/visit/?bta=323533&brand=fiverrcpa---------------------------------------------------Follow on Instagram!The Comics That We LoveFollow on Tiktok!The Comics that We LoveFollow on Bluesky!comicsthatwelove.bsky.social

Let us know if there's a topic you'd like us to cover! Welcome back to Green Industry Perspectives! In this episode, Jay Worth welcomes Marie Ambusk to the show!A bad experience with a landscaper set Marie on a nearly two-decade journey to make things right. When the street trees in her neighborhood failed after less than 20 years, she asked the landscape company replacing them what happened. The answer, "You get what you get, lady," made her blood boil. Since then, she's not only become a Master Gardener. She's developed a way to determine if trees are going to fail. Those street trees had root collar disorder. Once she realized the problem lay in the containers and growing phase, she developed a way to inspect the root systems of containerized trees. Using ground-penetrating radar (GPR), AI, and machine-learning, she's been able to map and grade the root systems of container trees to predict failure with a stunning degree of accuracy. Phase II of her project will focus on using the same GPR technology to map defects in planted trees, saving many hours of labor in excavation to look for problems. In this episode, Marie shares why customer satisfaction, employee opportunities, and company growth and profit make the difference to your success in the Green Industry. For her, they all boil down to one core issue: establishing trust. ---Check Out the SingleOps Events Page!Check Out the LMN Events Page!---Visit the Trees ROI WebsiteConnect with Marie on LinkedInVisit the Trees ROI Facebook PageVisit the TREEage Vermont Facebook Page

Dutch biotech Merus' EGFR x LGR5 bispecific antibody has caught investors' attention in the run-up to ASCO as a new approach to block EGFR signaling. On the latest BioCentury This Week podcast, BioCentury's analysts discuss Phase II data from Merus for petosemtamab as they preview the American Society of Clinical Oncology's upcoming annual meeting. The analysts also assess a setback in a gene therapy trial for Rocket Pharmaceuticals, renewed interest in cancer target EpCAM, and a flurry of biopharma activity on the Hong Kong stock exchange. Finally, the team previews BioCentury's second annual Grand Rounds R&D meeting, which takes place next week in Chicago. This episode was sponsored by Jeito Capital.View full story: https://www.biocentury.com/article/656038#biotech #biopharma #pharma #lifescience #RandD #DrugDevelopment00:01 - Sponsor Message: Jeito Capital24:52 - HK IPOs07:12 - ASCO16:37 - EpCAM20:16 - RocketTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

26 May 2025 - Strong results in soft tissue sarcoma have capped off a busy quarter of immunotherapy progress

Arecor Therapeutics PLC (AIM:AREC) CEO Sarah Howell talked with Proactive's Stephen Gunnion about the company's growing revenue streams, key partnerships, and ongoing developments within its proprietary pipeline. Howell discussed a new formulation development collaboration with Skye Bioscience, which aims to enhance Skye's CB1 inhibitor, nimacimab, currently in Phase II trials. The formulation will leverage Arecor's proprietary Arestat™ platform, with the goal of achieving higher concentration formats that can reduce dosing frequency and improve patient adherence. She noted that this is the third partnership Arecor has announced in 2025, highlighting the demand from pharmaceutical partners for the company's technology. “These are with enhanced properties. They bring improvements patients that are otherwise unachievable,” Howell said. Arecor currently has three products under license, including AT220, launched globally in late 2023 and now generating royalties. Products in development with Sanofi and another specialty pharmaceutical company, including AT351, also represent long-term revenue potential through milestone and royalty agreements. Looking ahead, Howell pointed to a strong pipeline focused on diabetes and obesity, including its proprietary ultra-concentrated insulin AT278, and a novel oral peptide delivery platform with expected preclinical data in H2 2025. Visit Proactive's YouTube channel for more interviews like this. Don't forget to like this video, subscribe to our channel, and enable notifications so you never miss an update. #ArecorTherapeutics #BiotechNews #PharmaceuticalPartnership #DiabetesInnovation #ObesityTreatment #InsulinDevelopment #AT220 #AT278 #OralPeptideDelivery #ProactiveInvestors

Robby Stanley and Paul Kuharsky, who is in for Rexrode the rest of the week, are talking all things Titans and NFL today.  What are some NFL headlines that are standing out early on?  The Titans are in Phase II of OTAs.  What do we think about how Callahan said the team is trying to address the mistakes from last season?  How much more sophisticated could the offense be this upcoming season?  Callahan gave an update on L'Jarius Sneed and his recovery from injury.

Nyrada Inc. CEO James Bonnar talked with Proactive about the company's progress developing a first-in-class TRPC ion channel blocker. This drug candidate is currently in a Phase I clinical trial and has demonstrated both neuroprotective and cardioprotective effects in preclinical models. Bonnar explained that TRPC channels play a crucial role in cellular injury, especially in heart and brain cells, and once these cells die, they are difficult to regenerate. Bonnar said the drug is showing efficacy in three key indications: stroke, traumatic brain injury, and myocardial infarction. “This drug is shown broad activity in these three indications, and it's really proving itself to be a Swiss Army knife type drug,” he noted. Recent preclinical results highlighted strong cardioprotective effects, including an 86% preservation of myocardial tissue and anti-arrhythmic activity — a key benefit given the risk of sudden cardiac death in heart attack patients. The Phase I study involves dose escalation in healthy volunteers, and so far, safety benchmarks have been met in the first two cohorts. Nyrada plans to complete the study by Q3, paving the way for Phase II trials in patient populations. For more updates on Nyrada and other biotech innovators, visit Proactive's YouTube channel. Don't forget to like this video, subscribe to the channel, and turn on notifications so you never miss an update. #Nyrada #BiotechStocks #TRPCBlocker #Cardioprotection #Neuroprotection #StrokeTreatment #HeartAttackRecovery #PharmaInnovation #DrugDevelopment #ClinicalTrials #ProactiveInvestors

Featuring an interview with Dr Rinath M Jesselsohn, including the following topics: Imlunestrant with or without abemaciclib in advanced breast cancer: Results of the Phase III EMBER-3 trial (0:00) Jhaveri KL et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med 2025;392(12):1189-202. Abstract  Jhaveri KL et al. Imlunestrant, an oral selective estrogen receptor degrader (SERD), as monotherapy & combined with abemaciclib, for patients with ER+, HER2- advanced breast cancer (ABC), pretreated with endocrine therapy (ET): Results of the Phase 3 EMBER-3 trial. San Antonio Breast Cancer Symposium 2024;Abstract GS1-01. Comprehensive genomic profiling of ESR1, PIK3CA, AKT1 and PTEN in HR-positive, HER2-negative metastatic breast cancer: Prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice (7:00) Bhave MA et al. Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: Prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice. Breast Cancer Res Treat 2024;207(3):599-609. Abstract Camizestrant, a next-generation oral selective estrogen receptor degrader (SERD), versus fulvestrant for postmenopausal women with estrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): A multi-dose, open-label, randomized, Phase II trial (10:25) Oliveira M et al. Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): A multi-dose, open-label, randomised, phase 2 trial. Lancet Oncol 2024;25(11):1424-39. Abstract Latest on SERDs: An education session at San Antonio Breast Cancer Symposium 2024 (13:57) Jeselsohn RM. Latest on selective estrogen receptor degraders (SERDs). San Antonio Breast Cancer Symposium 2024;Education Session 5. CME information and select publications

So fühlt sich der finale Countdown also an! Wir haben das Ende erreicht. Zumindest den Anfang vom Ende. Mit In das Licht von Claudia Gray startet die finale Welle der Hohen Republik. Nicht nur namentlich spiegelt das den einstigen Auftakt mit In die Dunkelheit wider, sondern auch inhaltlich wird ein Zirkelschluss gewagt. Dazwischen sind jedoch sehr viele Perspektivwechsel und damit oberflächliche Figurenzeichnungen versteckt, die kaum lange anhalten. Grund genug, dass Ines, Theo und Tobias genau über diesen Roman sprechen und auch identifizieren, warum weniger und dafür besser gezeichnete Figuren dem Roman gutgetan hätten. Zudem geht es um die Frage, was dieser Roman zum Gesamtprojekt so wirklich beiträgt. Außerdem sprechen wir darüber, wieso die Wookiees viel zu wenig Mitspracherecht erhalten und welche Implikationen das leider verursacht. Zeitmarken spoilerfreier Teil 00:00:00 - Begrüßung 00:02:17 - Erwartungen 00:04:20 - Die größte Überraschung 00:05:25 - Die größte Stärke 00:06:30 - Die größte Schwäche 00:07:54 - Einfluss auf die restlichen Werke? 00:10:11 - Rolle des Romans im Gesamtprojekt 00:11:48 - Was sollte man vorher kennen? 00:13:15 - Warum nicht Claudia Grays Stärke? Spoilerteil 00:17:09 - Abschlussfahrt nach Kashyyyk (Die Handlung) 00:21:08 - Extralange Exposition 00:34:28 - Das Point-of-View-Karussell 00:45:38 - Die Wookiees und die Kolonialherren 00:55:27 - Ro(w) down the Stream 01:03:14 - Disney+ präsentiert: Mkampa all along! 01:10:07 - Chilling in the Light 01:19:54 - Zweifel und Zuversicht 01:27:36 - Wer bin ich? 01:32:52 - Die Fünf-Minuten-Trauer 01:39:42 - Mit der Seuche leben lernen? 01:45:22 - Dez hab ich nicht erwartet! 01:47:25 - Fazit 01:53:12 - Ausblick 01:56:05 - Who lives, who dies, wo tells the story? Blick in die Datenbank Zur Werksübersicht von In das Licht, geschrieben von Claudia Gray Der Roman erschien am 1. April 2025 unter Into the Light bei Disney Lucasfilm-Press auf Englisch Am 15. April folgte dann ein englisches Hörbuch, gesprochen von Amber Lee Connors Die deutsche Version von Panini folgt voraussichtlich am 20. Mai 2025 Die Rezensionen Ines hat das Werk nach Release rezensiert und als Hauptproblem zu viel Personal im Roman identifiziert. Für sie fehlt der Fokuspunkt und damit die charakterliche Tiefe. Sie resümiert: "Leider schafft es Claudia Gray auch in ihrer letzten The High Republic-Geschichte nicht, an die Qualität ihrer eigenständigen Romane heranzukommen, da sie sich aufgrund eines riesigen Casts an Figuren verzettelt und dabei keiner Figur genügend Aufmerksamkeit schenkt. Kombiniert mit Pacing-Schwierigkeiten fühlt sich der Roman daher in Teilen gleichzeitig gehetzt und langatmig an. Trotzdem macht es Spaß, die liebgewonnenen Figuren weiter auf ihrem Weg zu begleiten und die magische Welt von Kashyyyk zu entdecken". Tobias rezensiert nach Erscheinen dann die deutsche Version. Einen Ausschnitt aus dieser Rezension könnt ihr bereits hier lesen: "In das Licht spiegelt dem Titel nach den ersten YA-Roman der Hohen Republik – In die Dunkelheit – wider. Das erfüllt er auch inhaltlich und schließt die Klammer damit zufriedenstellend. Wie Claudia Gray das jedoch herleitet und wie sprunghaft sie in ihrer Wahl der Hauptfiguren ist, stört das Gesamtbild. Mit keiner Figur eifern wir so wirklich mit, alle sind Plot-Träger ohne viel emotionale Momente oder gar inneren Monologen. Wenn diese jedoch mal hervorstechen, wird der Wunsch nur größer, mehr darüber zu erfahren. Doch da muss schon der vierte PoV in diesem Kapitel auch noch seinen Senf dazugeben. Am Ende entsteht eine Melange, die zwar das Projekt um einen Etappensieg bereichert, selbst aber nicht zu den Werken gehört, die der Hohen Republik ihre Seele geben". Den JediCast abonnieren Wir sind auf allen gängigen Podcast-Plattformen vertreten! Abonniert uns also gerne auf Spotify, Apple Podcasts, Google Podcasts (etc.), oder fügt bequem unsere Feeds in euren präferierten Podcast-Player ein. Alle Links dazu findet ihr oben unter dem Player verlinkt sowie auch jederzeit unter dem Audioplayer in der rechten Sidebar. Wir freuen uns auch immer über Bewertungen auf den jeweiligen Podcast-Seiten. Falls ihr umfangreichere Anmerkungen habt, schreibt auch gerne eine Mail an podcast@jedi-bibliothek.de! Eure Meinung Was haltet ihr von Claudia Grays finalem YA-Roman der Hohen Republik? Teilt ihr unsere doch eher kritische Meinung oder habt ihr euch voll in den Figuren und der Welt verloren? Wie blickt ihr auf den finalen Erwachsenenroman und welche Wünsche und Ängste habt ihr bezüglich der Luminous Nine? Star Wars: Die Hohe Republik ist ein mehrjähriges Buch- und Comicprogramm, das hunderte Jahre vor den Skywalker-Filmen spielt und die Jedi in ihrer Blütezeit zeigt. Weitere Infos, News, Podcasts und Rezensionen gibt es in unserem Portal und in der Datenbank. Beachtet auch unsere Guides zur Lesereihenfolge von Phase I, Phase II und Phase III.

Phase II of the offseason program is underway in Tempe as the Arizona Cardinals rookies join the veterans for work. Craig Grialou, Paul Calvisi and former Cardinals QB Drew Stanton talk about building in the offseason, rookie CB Will Johnson's fit in Nick Rallis' defense, what kind of role we'll see from OLB Jordan Burch and if a push to start is realistic for sixth-round guard Hayden Conner out of Texas.See omnystudio.com/listener for privacy information.

Phase II of the offseason program is underway in Tempe as the Arizona Cardinals rookies join the veterans for work. Craig Grialou, Paul Calvisi and former Cardinals QB Drew Stanton talk about building in the offseason, rookie CB Will Johnson's fit in Nick Rallis' defense, what kind of role we'll see from OLB Jordan Burch and if a push to start is realistic for sixth-round guard Hayden Conner out of Texas.See omnystudio.com/listener for privacy information.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.President Donald Trump has issued an executive order to expedite the timeline for building new facilities in the US while increasing inspections on foreign plants. Despite a drop in venture capital fundraising in the first quarter of the year, large investments are still being made in the pharmaceutical industry. Companies like BMS are investing billions in US manufacturing despite potential tariffs. Vertex has seen success with their non-opioid pain drug launch and biopharma venture capital fundraising has declined, but median deal sizes remain high. Lotte Biologics offers specialized ADC manufacturing services in Syracuse, NY. Other news includes Lilly's ALS pipeline expansion, states suing to block HHS cuts, and layoffs at PTC despite a Phase II win. Thank you for tuning in to today's episode of Pharma and Biotech daily. Let's dive into the latest updates from the industry.

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Dimitrios Goundis, CEO of Kither Biotech. Kither is a Phase I, soon to be Phase II, Italian biotech focused on respiratory diseases such as cystic fibrosis. This episode explores how emerging biotech strategies are advancing treatments for respiratory diseases like cystic fibrosis, with a focus on targeted drug delivery, clinical trial progression, and the evolving biotech landscape in Europe. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

  Lyssa Rome is a speech-language pathologist in the San Francisco Bay Area. She is on staff at the Aphasia Center of California, where she facilitates groups for people with aphasia and their care partners. She owns an LPAA-focused private practice and specializes in working with people with aphasia, dysarthria, and other neurogenic conditions. She has worked in acute hospital, skilled nursing, and continuum of care settings. Prior to becoming an SLP, Lyssa was a public radio journalist, editor, and podcast producer. In this episode, Lyssa Rome interviews Dr. Suma Devanga about collaborative referencing, gesture, and building rich communicative environments for people with aphasia.   Guest info Dr. Suma Devanga is an assistant professor in the Department of Communication Disorders and Sciences at Rush University Medical Center, Chicago, where she also serves as the director of the Aphasia Research Lab. She completed her PhD in Speech and Hearing science from the University of Illinois. Urbana Champaign in 2017. Dr. Devanga is interested in studying aphasia interventions and their impacts on people's everyday communication. Her recent work includes investigating a novel treatment called the Collaborative Referencing Intervention for Individuals with aphasia, using discourse analysis methods and patient reported outcome measures, studying group-based treatments for aphasia, and studying the use of gestures in aphasia. Additionally, she is involved in teaching courses on aphasia and cognitive communication disorders to graduate SLP students at Rush. She also provides direct patient care and graduate clinical supervision at Rush outpatient clinics.   Listener Take-aways In today's episode you will: Understand the role of collaborative referencing in everyday communication. Learn about Collaborative Referencing Intervention. Describe how speech-language pathologists can create rich communicative environments.   Edited transcript   Lyssa Rome Welcome to the Aphasia Access Aphasia Conversations Podcast. I'm Lyssa Rome. I'm a speech language pathologist on staff at the Aphasia Center of California, and I see clients with aphasia and other neurogenic communication disorders in my LPAA-focused private practice. I'm also a member of the Aphasia Access podcast Working Group. Aphasia Access strives to provide members with information, inspiration, and ideas that support their aphasia care through a variety of educational materials and resources.   I'm today's host for an episode that will feature Dr. Suma Devanga, who is selected as a 2024 Tavistock Trust for Aphasia Distinguished Scholar, USA and Canada. In this episode, we'll be discussing Dr. Devanga's research on collaborative referencing, gesture, and building rich communicative environments for people with aphasia.   Suma Devanga is an assistant professor in the Department of Communication Disorders and Sciences at Rush University Medical Center, Chicago, where she also serves as the director of the Aphasia Research Lab. She completed her PhD in Speech and Hearing science from the University of Illinois. Urbana Champaign in 2017. Dr. Devanga is interested in studying aphasia interventions and their impacts on people's everyday communication. Her recent work includes investigating a novel treatment called the Collaborative Referencing Intervention for Individuals with aphasia, using discourse analysis methods and patient reported outcome measures, studying group-based treatments for aphasia, and studying the use of gestures in aphasia. Additionally, she is involved in teaching courses on aphasia and cognitive communication disorders to graduate SLP students at Rush. She also provides direct patient care and graduate clinical supervision at Rush outpatient clinics. Suma Devanga, thank you so much for joining us today. I'm really happy to be talking with you.   Suma Devanga Thank you, Lyssa, thank you for having me. And I would also like to thank Aphasia Access for this wonderful opportunity, and the Tavistock Trust for Aphasia and the Duchess of Bedford for recognizing my research through the Distinguished Scholar Award.   Lyssa Rome So I wanted to start by asking you how you became interested in aphasia treatment.   Suma Devanga I became interested in aphasia during my undergraduate and graduate programs, which was in speech language pathology in Mysore in India. I was really drawn to this population because of how severe the consequences were for these individuals and their families after the onset of aphasia. So I met hundreds of patients and families with aphasia who were really devastated by this sudden condition, and they were typically left with no job and little means to communicate with family and friends. So as a student clinician, I was very, very motivated to help these individuals in therapy, but when I started implementing the treatment methods that I had learned, what I discovered was that my patients were showing improvements on the tasks that we worked on in therapy. Their scores on clinical tasks also were improving, but none of that really mattered to them. What they really wanted was to be able to easily communicate with family, but they continued to struggle on that, and none of the cutting-edge treatment methods that I learned from this highly reputable program in India were impacting my patients' lives.   So I really felt lost, and that is when I knew that I wanted to do a PhD and study this topic more closely, and I was drawn to Dr. Julie Hengst's work, which looked at the bigger picture in aphasia. She used novel theoretical frameworks and used discourse analysis methods for tracking patient performance, as opposed to clinical tests. So I applied to the University of Illinois PhD program, and I'm so glad that she took me on as her doctoral student. And so that is how I ended up moving from India to the US and started my work in aphasia.   Lyssa Rome I think that a lot of us can probably relate to what you're describing—that just that feeling of frustration when a patient might improve on some sort of clinical tasks, but still says this is not helping me in my life, and I know that for me, and I think for others, that is what has drawn us to the LPAA.   I wanted to sort of dive into your research by asking you a little bit more about rich communicative environments, and what you mean by that, and what you mean when you talk about or write about distributed communication frameworks.   Suma Devanga So since I started my PhD, I have been interested in understanding how we can positively impact everyday communication for our patients with aphasia. As a doctoral student, I delved more deeply into the aphasia literature and realized that what I observed clinically with my patients in India was consistent with what was documented in the literature, and that was called the clinical-functional gap. And this really refers to the fact that we have many evidence-based aphasia treatments that do show improvements on clinical tasks or standardized tests, but there is very limited evidence on these treatments improving the functional use of language or the everyday communication, and this remains to be true even today.   So I think it becomes pretty important to understand what we are dealing with, like what is everyday communication? And I think many aphasia treatments have been studying everyday communication or conversational interactions by decontextualizing them or reducing them into component parts, like single words or phrases, and then we work our way up to sentence structures. Right? So this approach has been criticized by some researchers like Clark, who is an experimental psychologist, and he called such tasks as in vacuo, meaning that they are not really capturing the complexity of conversational interactions. So basically, even though we are clinicians, our ultimate goal is improving everyday communication, which is rich and emergent and complex, we somehow seem to be using tasks that are simplified and that removes all of these complexities and focuses more on simple or specific linguistic structures. So to understand the complexities of everyday communication, we have shifted to the distributed communication framework, which really originates from the cultural historical activity theories and theories from linguistic anthropology.   Dr. Julie Hengst actually proposed the distributed communication theory in her article in the Journal of Communication Disorders in 2015, which highlights that communication is not just an individual skill or a discrete concept, but it is rather distributed. And it is distributed in three ways: One is that it is distributed across various resources. We communicate using multiple resources, not just language. We sign, we use gestures, or facial expressions. We also interpret messages using such resources like dialects and eye gaze and posture, the social context, cultural backgrounds, the emotional states that we are in, and all of that matters. And we all know this, right? This is not new, and yet, we often give credit to language alone for communication, when in reality, we constantly use multiple resources. And the other key concept of distributed communication theory is that communication is embedded in socio- cultural activities. So depending on the activity, which can be a routine family dinnertime conversation or managing relationships with your co workers, the communicative resources that you use, their motives, and the way you would organize it, all of that would vary. And finally, communication is distributed across time. And by that we mean that people interpret and understand present interactions through the histories that they have experienced over time. For example, if you're at work and your manager says you might want to double check your reports before submitting them based on prior interactions with the manager and the histories you've shared with them, you could interpret that message either as a simple suggestion or that there is a lack of trust in your work. So all in all, communication, I think, is a joint activity, and I think we should view it as a joint activity, and it depends on people's ability to build common ground with one another and draw from that common ground to interpret each other's messages.   Lyssa Rome I feel like that framework is really helpful, and it makes a lot of sense, especially as a way of thinking about the complexity of language and the complexity of what we're trying to do when we are taking a more top-down approach. So that's the distributed communication theory. And it sounds like the other framework that has really guided your research is rich communicative environments. And I'm wondering if you could say a little bit more about that.   Suma Devanga Absolutely. So this work originates from about 80 years of research in neuroscience, where rodents and other animals with acquired brain injuries showed greater neuroplastic changes and improved functions when they were housed in complex environments. In fact, complex environments are considered to be the most well replicated approach to improve function in animal models of acquired brain injury.   So Dr. Julie Hengst, Dr. Melissa Duff, and Dr. Theresa Jones translated these findings to support communication for humans with acquired brain injuries. And they called it the rich communicative environments. The main goal of this is to enrich the clinical environments. And how we achieve that is by ensuring that there is meaningful complexity in our clinical environments, and that you do that by ensuring that our patients, families, and clinicians use multimodal resources, and also to aim for having multiple communication partners within your sessions who can fluidly shift between various communicative roles, and to not just stay in that clinician role, for example.   Another way to think about enriching clinical environments is to think about ensuring that there is voluntary engagement from our patients, and you do that by essentially designing personally meaningful activities, rather than focusing on rehearsing fixed linguistic form or having some predetermined goals.   And the other piece of the enrichment is, how do we ensure there is a positive experiential quality for our patients within our sessions. And for this rather than using clinician-controlled activities with rigid interactional roles, providing opportunities for the patients to share stories and humor would really, you know, ensure that they are also engaging with the tasks with you and having some fun. So all of this put together would lead to a rich communicative environment.   Lyssa Rome It sounds like what you're describing is the kind of speech therapy environment and relationship that is very much person-centered and focused on natural communication, or natural communicative contexts and the kinds of conversations that people have in their everyday lives, rather than more sort of strict speech therapy protocol that might have been more traditional. I also want to ask you to describe collaborative referencing and collaborative referencing intervention.   Suma Devanga Yes, absolutely. So traditionally, our discipline has viewed word-finding or naming as a neurolinguistic process where you access semantic meanings from a lexicon, which you use to generate verbal references. And that theoretical account conceptualizes referencing as an isolated process, where one individual has the skill of retrieving target references from their stores of linguistic forms and meanings, right? So in contrast to that, the distributed communication perspective views referencing as a process where speakers' meanings are constructed within each interaction, and that is based on the shared histories of experiences with specific communication partners and also depending on the social and physical contexts of the interaction as well.   Now this process of collaborative referencing is something that we all do every single day. It is not just a part of our everyday communication, but without collaborative referencing, you cannot really have a conversation with anyone. You need to have some alignment, some common ground for communicating with others. This is a fundamental feature of human communication, and this is not new. You know, there is lots of work being done on this, even in childhood language literature as well.   Collaborative referencing was formally studied by Clark, who is the experimental psychologist. And he studied this in healthy college students, and he used a barrier task experiment for it. So a pair of students sat across from each other with a full barrier that separated them so they could not see each other at all, and each student had a board that was numbered one through 12, and they were given matching sets of 12 pictures of abstract shapes called tangrams. One participant was assigned as the director, who arranged the cards on their playing board and described their locations to the other, who served as the matcher and matched the pictures to their locations on their own board. So the pair completed six trials with alternating turns, and they use the same cards with new locations for each trial. And what they found was that the pairs had to really collaborate with each other to get those descriptions correct so that they are placed correctly on the boards.   So in the initial trials, the pairs had multiple turns of back and forth trying to describe these abstract shapes. For example, one of the pictures was initially described as “This picture that looks like an angel or something with its arms wide open.” And there had to be several clarifying questions from the partner, and then eventually, after playing with this picture several times, the player just had to say “It's the angel,” and the partner would be able to know which picture that was so as the pairs built their common ground, the collaborative effort, or the time taken to complete each trial, and the number of words they used and the number of turns they took to communicate about those pictures declined over time, and the labels itself, or the descriptions of pictures, also became more streamlined as the as time went by.   So Hengst and colleagues wanted to study this experiment in aphasia, TBI, amnesia, and Alzheimer's disease as well. So they adapted this task to better serve this population and also to align with the distributed communication framework. And surprisingly, they found consistent results that despite aphasia or other neurological conditions, people were still able to successfully reference, decrease collaborative effort over time and even streamline their references. But more surprisingly, people were engaged with one another. They were having really rich conversations about these pictures. They were sharing jokes, and really seemed to be enjoying the task itself.   So Hengst and colleagues realized that this has a lot of potential, and they redesigned the barrier task experiment as a clinical treatment using the principles of the distributed communication framework and the rich communicative environment. So that redesign included replacing the full barrier with a partial barrier to allow multimodal communication, and using personal photos of the patients instead of the abstract shapes to make it more engaging for the patients, and also asking participants to treat this as a friendly game and to have fun. So that is the referencing itself and the research on collaborative referencing, and that is how it was adapted as a treatment as well.   And in order to help clinicians easily implement this treatment, I have used the RTSS framework, which is the rehabilitation treatment specification system, to explain how CRI works and how it can be implemented. And this is actually published, and it just came out in the most recent issue in the American Journal of Speech Language Pathology, which I'm happy to share.   Lyssa Rome And we'll put that link into the show notes.   Suma Devanga Perfect. So CRI is designed around meaningful activities like the game that authentically provides repeated opportunities for the client and the clinician to engage in the collaborative referencing process around targets that they really want to be talking about, things that are relevant to patients, everyday communication goals, it could be things, objects of interest, and not really specific words or referencing forms.   So the implementation of the CRI involves three key ingredients. One is jointly developing the referencing targets and compiling the images so clinicians would sit down with the patients and the families to identify at least 30 targets that are meaningful and important to be included in the treatment. And we need two perspectives, or two views, or two pictures related to the same target that needs to be included in the treatment. So we will have 60 pictures overall. An example is two pictures from their wedding might be an important target for patients to be able to talk about. Two pictures from a Christmas party, you know, things like that. So this process of compilation of photos is also a part of the treatment itself, because it gives the patients an opportunity to engage with the targets.   The second ingredient is engaging in the friendly gameplay itself. And the key really here is the gameplay and to treat it as a gameplay. And this includes 15 sessions with six trials in each session, where you, as the clinician and the client will both have matching sets of 12 pictures, and there is a low barrier in between, so you cannot see each other's boards, but you can still see the other person. So you will both take turns being the director and the matcher six times, and describe and match the pictures to their locations, and that is just the game. The only rule of the game is that you cannot look over the barrier. You are encouraged to talk as much as you like about the pictures. In fact, you are encouraged to talk a lot about the pictures and communicate in any way.   The third ingredient is discussing and reflecting on referencing. And this happens at the end of each session where patients are asked to think back and reflect and say what the agreed upon label was for each card. And this, again, gives one more opportunity for the patients to engage with the target.   The therapeutic mechanism, or the mechanism of action, as RTSS likes to call it, is the rich communicative environment itself, you know, and how complex the task is, and how meaningful and engaging the task has to be, as well as the repeated engagement in the gameplay, because we are doing this six times in each session, and we are repeatedly engaging with those targets when describing them and placing them.   So what we are really targeting with CRI is collaborative referencing and again, this does not refer to the patient's abilities to access or retrieve those words from their stores. Instead, we are targeting people's joint efforts in communicating about these targets, their efforts in building situated common ground. That's what we are targeting. We are targeting their alignment with one another, and so that is how we define referencing. And again, we are targeting this, because that is how you communicate every day.   Lyssa Rome That sounds like a really fascinating and very rich intervention. And I'm wondering if you can tell us a little bit about the research that you've done on it so far.   Suma Devanga Absolutely. So in terms of research on CRI thus far, we have completed phase one with small case studies that were all successful, and my PhD dissertation was the first phase two study, where we introduced an experimental control by using a multiple-probe, single-case experimental design on four people with aphasia, and we found significant results on naming. And since then, I have completed two replication studies in a total of nine participants with aphasia. And we have found consistent results on naming. In terms of impact on everyday interactions, we have found decreased trouble sources, or communicative breakdowns, you can call it, and also decreased repairs, both of which indicated improved communicative success within conversational interactions. So we are positive, and we plan to continue this research to study its efficacy within a clinical trial.   Lyssa Rome That's very encouraging. So how can clinicians target collaborative referencing by creating a rich communicative environment?   Suma Devanga Yeah, well, CRI is one approach that clinicians can use, and I'm happy to share the evidence we have this far, and there is more to come, hopefully soon, including some clinical implementation studies that clinicians can use. But there are many other ways of creating rich communicative environments and targeting referencing within clinical sessions. I think many skilled clinicians are already doing it in the form of relationship building, by listening closely to their patients, engaging with them in authentic conversations, and also during education and counseling sessions as well.   In addition to that, I think group treatment for aphasia is another great opportunity for targeting collaborative referencing within a rich communicative environment. When I was a faculty at Western Michigan University, I was involved in their outpatient aphasia program, where they have aphasia groups, and patients got to select which groups they want to participate in. They had a cooking group, a music group, a technology group, and so on. And I'm guessing you do this too at the Aphasia Center of California. So these groups definitely create rich communicative environments, and people collaborate with each other and do a lot of referencing as well. So I think there is a lot that can be done if you understand the rich communicative environment piece.   Lyssa Rome Absolutely. That really rings true to me. So often in these podcast interviews, we ask people about aha moments, and I'm wondering if you have one that you wanted to share with us.   Suma Devanga Sure. So you know how I said that getting the pictures for the CRI is a joint activity? Patients typically select things that they really want to talk about, like their kids' graduation pictures, or things that they are really passionate about, like pictures of their sports cars, or vegetable gardens, and so on. And they also come up with really unique names for them as well, while they are playing with those pictures during the treatment. And when we start playing the game, clinicians usually have little knowledge about these images, because they're all really personal to the patients, and they're taken from their personal lives, so they end up being the novices, while the patients become the experts. And my patients have taught me so much about constructing a house and all about engines of cars and things like that that I had no knowledge about. But in one incident, when I was the clinician paired with an individual with anomic aphasia, there was a picture of a building that she could not recognize, and hence she could not tell me much at all. And we went back and forth several times, and we finally ended up calling it the “unknown building.” Later, I checked my notes and realized that it was where she worked, and it was probably a different angle, perhaps, which is why she could not recognize it. But even with that new information, we continue to call it the “unknown building,” because it became sort of an internal joke for us. And later I kept thinking if I had made a mistake and if we should have accurately labeled it. That is when it clicked for me that CRI is not about producing accurate labels, it is about building a common ground with each other, which would help you successfully communicate with that person. So you're targeting the process of referencing and not the reference itself, because you want your patients to get better at the process of referencing in their everyday communication. And so that was my aha moment.   Lyssa Rome Yeah, that's an amazing story, because I think that that gets to that question sort of of the why behind what we're doing, right? Is it to say the specific name? I mean, obviously for some people, yes, sometimes it is. But what is underlying that? It's to be able to communicate about the things that are important to people. I also wanted to ask you about another area that you've studied, which is the use of gesture within aphasia interventions. Can you tell us a little bit more about that?   Suma Devanga Yes. So this work started with my collaboration with my friend and colleague, Dr. Mili Mathew, who is at Molloy University in New York, and our first work was on examining the role of hand gestures in collaborative referencing in a participant who had severe Wernicke's aphasia, and he frequently used extensive gestures to communicate. So when he started with CRI his descriptions of the images were truly multimodal. For example, when he had to describe a picture of a family vacation in Cancun, he was, you know, he was verbose, and there was very little meaningful content that was relevant in his spoken language utterances. But he used a variety of iconic hand gestures that were very meaningful and helpful to identify what he was referring to. As the sessions went on with him, his gestural references also became streamlined, just like the verbal references do, and that we saw in other studies. And that was fascinating because it indicated that gestures do play a big role in the meaning-making process of referencing.   And in another study on the same participant, we explored the use of hand gestures as treatment outcome measures. This time, we specifically analyzed gestures used within conversations at baseline treatment, probe, and maintenance phases of the study. And we found that the frequency of referential gestures, which are gestures that add meaning, that have some kind of iconics associated with them, those frequencies of gestures decreased with the onset of treatment, whereas the correct information units, or CIUS, which indicate the informativeness in the spoken language itself, increased. So this pattern of decrease in hand gestures and increase in CIUS was also a great finding. Even though this was just an exploratory study, it indicates that gestures may be included as outcome measures, in addition to verbal measures, which we usually tend to rely more on. And we have a few more studies coming up that are looking at the synchrony of gestures with spoken language in aphasia, but I think we still have a lot more to learn about gestures in aphasia.   Lyssa Rome It seems like there that studying gestures really ties in to CRI and the rich communicative environments that you were describing earlier, where the goal is not just to verbally name one thing, but rather to get your point across, where, obviously, gesture is also quite useful. So I look forward to reading more of your research on that as it comes out. Tell us about what you're currently working on, what's coming next.   Suma Devanga Currently, I am wrapping up my clinical research grant from the ASH Foundation, which was a replication study of the phase two CRI so we collected data from six participants with chronic aphasia using a multiple-probe, single-case design, and that showed positive results on naming, and there was improved scores on patient reports of communication confidence, communicative participation, and quality of life as well. We are currently analyzing the conversation samples to study the treatment effects.   I also just submitted a grant proposal to extend the study on participants with different severities of aphasia as well. So we are getting all the preliminary data at this point that we need to be able to start a clinical trial, which will be my next step.   So apart from that, I was also able to redesign the CRI and adapt it as a group-based treatment with three participants with aphasia and one clinician in a group. I actually completed a feasibility study of it, which was successful, and I presented that at ASHA in 2023. And I'm currently writing it up for publication, and I also just secured an internal grant to launch a pilot study of the group CRI to investigate the effects of group CRI on communication and quality of life.   Lyssa Rome Well, that's really exciting. And again, I'm really looking forward to reading additional work as it comes out. As we wrap up. What do you want clinicians to take away from your work and to take away from this conversation we've had today?   Suma Devanga Well, I would want clinicians to reflect on how their sessions are going and think about how to incorporate the principles of rich communicative environments so that they can add more meaningful complexity to their treatment activities and also ensure that their patients are truly engaging with the tasks and also having some fun. And I would also tell the clinicians that we have strong findings so far on CRI with both fluent and non-fluent aphasia types. So please stay tuned and reach out to me if you have questions or want to share your experiences about implementing this with your own patients, because I would love to hear that.   Lyssa Rome Dr. Suma Devanga, it has been great talking to you and hearing about your work. Thank you so much for sharing it with us.   Suma Devanga It was fantastic talking about my work. Thank you for giving me this platform to share my work with you all. And thank you, Lyssa for being a great listener.   Lyssa Rome Thanks also to our listeners for the references and resources mentioned in today's show. Please see our show notes. They're available on our website, www.aphasiaaccess.org. There, you can also become a member of our organization, browse our growing library of materials, and find out about the Aphasia Access Academy. If you have an idea for a future podcast episode, email us at info@aphasiaaccess.org. Thanks again for your ongoing support of aphasia. Access. For Aphasia Access Conversations. I'm Lyssa Rome.       References   Devanga, S. R. (2025). Collaborative Referencing Intervention (CRI) in Aphasia: A replication and extension of the Phase II efficacy study. American Journal of Speech-Language Pathology. Advance online publication. https://doi.org/10.1044/2024_AJSLP-24-00226   Devanga, S. R., Sherrill, M., & Hengst, J. A. (2021). The efficacy of collaborative referencing intervention in chronic aphasia: A mixed methods study. American Journal of Speech Language Pathology, 30(1S), 407-424. https://doi.org/10.1044/2020_AJSLP-19-00108    Hengst, J. A., Duff, M. C., & Jones, T. A. (2019). Enriching communicative environments: Leveraging advances in neuroplasticity for improving outcomes in neurogenic communication disorders. American Journal of Speech-Language Pathology, 28(1S), 216–229. https://doi.org/10.1044/2018_AJSLP-17-0157   Hengst, J. A. (2015). Distributed communication: Implications of cultural-historical activity theory (CHAT) for communication disorders. Journal of Communication Disorders, 57, 16–28. Https://doi.org/10.1016/j.jcomdis.2015.09.001   Devanga, S. R., & Mathew, M. (2024). Exploring the use of co-speech hand gestures as treatment outcome measures for aphasia. Aphasiology. Advanced online publication. https://doi.org/10.1080/02687038.2024.2356287   Devanga, S. R., Wilgenhof, R., & Mathew, M. (2022). Collaborative referencing using hand gestures in Wernicke's aphasia: Discourse analysis of a case study. Aphasiology, 36(9), 1072-1095. https://doi.org/10.1080/02687038.2021.1937919    

Die Abenteuer-Reihe von Die Hohe Republik ist ein stetes Auf und Ab. Während sie in der ersten Phase noch mit Metaphern und intelligenter Verwebung überzeugte, scheiterte sie in der zweiten Phase an ihrer Belanglosigkeit. Doch in der dritten Phase geht es endlich zurück zu den alten Charakteren und damit zurück zu alter Stärke - oder? Darüber reden Ines und Tobias in dieser Ausgabe des JediCast und zeichnen ein eher enttäuschtes Bild. Die Figuren sind zu undefiniert, treten beliebig in den Vorder- und Hintergrund. Neue Figuren werden kaum bis gar nicht etabliert, die Handlung ist zerstückelt und unfokussiert und nicht mal mehr die metaphorische Botschaft aus der ersten Phase verfängt noch. Wieso all das so ist, soll dieser Podcast klären als auch die Frage, warum ausgerechnet Zeen zur BrideZilla wird! Zeitmarken spoilerfreier Teil 00:00:00 - Begrüßung 00:02:08 - Eindruck von der bisherigen Reihe 00:04:02 - Das Amnesie-Problem 00:06:36 - Die Zeichnungen Spoilerteil 00:09:43 - BrideZilla 00:15:00 - Kennt man die? 00:19:46 - Ein Hauch von Politik 00:24:16 - Am Anfang war die Amnesie 00:27:53 - Krix macht nix? 00:30:44 - Sevran all along? 00:34:48 - Keine Fallhöhe 00:36:00 - Niv und das Nichtstun 00:37:24 - Frage der Zugänglichkeit 00:44:50 - TriVaEriadu 00:49:33 - Düstere Aussichten 00:54:00 - Major Tom zu wörtlich genomm' 00:58:49 - Lula und die falsche Symbolik Blick in die Datenbank Die Hohe Republik - Abenteuer, geschrieben von Daniel José Older, erschien in mehreren Einzel-Arcs: Unter Die Hohe Republik - Abenteuer, Band 8 wurden gesammelt von Panini: What the Mikkian Wants The Ballad of Tartak Vil Now or Never Unter Die Hohe Republik - Abenteuer, Band 9 wurden gesammelt von Panini: Eriadu Games The Evacuation Run Tarkin Family Business Die Rezensionen Ines hat die einzelnen Ausgaben im Rahmen der Dark-Horse-Rezensionen behandelt. Ihre Meinung zur Handlung ist dabei - surprise - deckungsgleich mit der im Podcast. Zu viele Charaktere, die nicht eingeführt werden und zu wenig eigentliche Handlung, machen das Ganze beliebig und schlechter als in der ersten Phase. Tobias hat sich des ersten Panini-Bands angenommen und wird sich dem zweiten noch widmen. Gerade die viele Zeit, die gebraucht wird, um wieder zu einem Status Quo zu kommen, haben ihm den ersten Band madig gemacht. Der zweite wird insgesamt durch fehlenden Fokus auf eine Handlung und beliebige Hauptfiguren nicht viel besser abschneiden. Den JediCast abonnieren Wir sind auf allen gängigen Podcast-Plattformen vertreten! Abonniert uns also gerne auf Spotify, Apple Podcasts, Google Podcasts (etc.), oder fügt bequem unsere Feeds in euren präferierten Podcast-Player ein. Alle Links dazu findet ihr oben unter dem Player verlinkt sowie auch jederzeit unter dem Audioplayer in der rechten Sidebar. Wir freuen uns auch immer über Bewertungen auf den jeweiligen Podcast-Seiten. Falls ihr umfangreichere Anmerkungen habt, schreibt auch gerne eine Mail an podcast@jedi-bibliothek.de! Eure Meinung Wie seid ihr in die dritte Phase mit Lula, Zeen, Qort, Farzala, und Hauptfigur 5 bis 99 gestartet? Hat euch die Handlung(en) mitgenommen oder sucht auch ihr - wie Theseus - Ariadnes roten Faden? Schreibt es uns gerne in die Kommentare. Wenn ihr uns unterstützen wollt, könnt ihr das seit neuestem über unseren Buymeacoffee-Link tun. Star Wars: Die Hohe Republik ist ein mehrjähriges Buch- und Comicprogramm, das hunderte Jahre vor den Skywalker-Filmen spielt und die Jedi in ihrer Blütezeit zeigt. Weitere Infos, News, Podcasts und Rezensionen gibt es in unserem Portal und in der Datenbank. Beachtet auch unsere Guides zur Lesereihenfolge von Phase I, Phase II und Phase III.

Can a glass of pomegranate juice really help slow the growth of prostate cancer? In this episode of The Moss Report, Ben Moss and Dr. Ralph W. Moss take a deep dive into the clinical research on pomegranate and cancer—especially prostate cancer. They explore landmark studies from Johns Hopkins and UCLA, uncover the political backstory behind the POMx extract, and offer practical guidance for integrating pomegranate into a cancer-fighting or preventative diet. Dr. Moss also shares his personal use of pomegranate powder, discusses antioxidant synergy, and introduces options that reduce sugar intake without sacrificing benefits. A compelling look at how traditional foods meet cutting-edge science. “Fill up that self-help space with scientifically documented ways to reduce your cancer risk.” – Dr. Ralph W. Moss

Just in time for the weekend - let's get some 90's trance going! Additive Records was a UK-based sub-label of the legendary Positiva Records, and while it may not have had the flashiest branding, it played a critical role in shaping the underground-to-mainstream pipeline of late '90s and early 2000s electronic music. Think of it as Positiva's cooler, more discerning younger sibling — the one digging through crates while the big brother was cashing radio hits. Where Positiva was known for massive crossover dance anthems and polished commercial smashes, Additive was the vinyl-only proving ground — a boutique imprint designed to test the club viability of more progressive and experimental tracks. If a release did well on Additive, chances were good it might graduate to a full-blown Positiva release with the marketing machine behind it. This was music for DJs, pure and simple. High-quality 12” pressings, remixes that weren't afraid to be 9 minutes long, and a catalogue full of gems that would heat up the dancefloor before most people even knew the name of the track. I knew it for trance, but it also churned out massive progressive house records (the real progressive house, not this modern "Prog House" stuff) so we'll warm up this episode with a few house cuts before breaking away into their better known trance cuts. Track listing: 01. White Trash - Acid People 02. Fletch - Space (Loudmouth Remix)
 03. DJ Sandy vs Housetrap - Overdrive (Moguia's ‘Amnesia Fog Generator') 04. Novy vs Eniac - Pumpkin (Bluefish Remix) 05. Adam Dived - Deep Inside (King of Spain Remix) 06. Simon - Free At Last (Bushwacka's ‘Class of '88' Remix) 07. Electric Deluxe - Electric Deluxe 08. Adam Dived - State of Panic 09. Ayla - Ayla 10. Little Jam - Black Hill (X-Cabs ‘Hells Bells' Mix) 11. The Gate - Iron Eden (Terra Ferma Remix) 12. HH - ICE 794 (Thanks to Berlin Dub Mix) 13. Marc Et Claude - La (Lange Remix) 14. Watergate - Heart of Asia (DJ Quicksilver ‘Q' Mix) 15. Der Dritte Raum - Hale Bopp (Nick Warren & Starecase ‘Jackdaw' Mix) 16. Aurora - Hear You Calling (Fire & Ice Remix) 17. Force Majeure - Redemption (The Thrillseekers ‘Redeemed' Mix) 18. Jon the Dentist - Terminate (Yves Deruyter Remix) 19. Brainbug - Nightmare (A Synergetic Mix) 20. Chris Raven - I Know You Love Me Too (Bruce Norris Mix) 21. 16C+ - Under 4 Ever (Gil's ‘Spiritual' Remix) 22. Der Dritte Raum - Trommelmaschine 23. DJ Sakin & Friends - Protect Your Mind (Suspicious Remix) 24. Fridge - Paradise (Push Remix) 25. Velvet Girl - Walking In Sunshine (Philippe Van Mullem Remix) 26. Sosa - The Wave (DJ Taucher Remix) 27. Jon the Dentist - Shinto (Aaron Olson & Bryn Liedl Remix) 28. Commander Tom - Are Am Eye? (Yves Deruyter Remix) 29. GrooveZone - Eisbaer (Viper Remix) 30. DJ Taucher - Bizarre (Extended Club Mix) 31. Scot Project - U (I Got A Feeling) (Mark Sherry's ‘Outburst' Remix) 32. Red Light District - Did You Hear Me? (Phase II) 33. BBE - Seven Days and One Week (Club Mix)  

In this episode of The Scope of Things, host Deborah Borfitz covers the latest news, including setting expectations for Phase II cancer trials, key learnings about dementia from the Nun Study, links between cardiovascular disease and mild cognitive impairment, using aspirin to prevent cancer spread, a clinical trial map to improve study access, and a naturally occurring molecule that rivals Ozempic in its weight loss potential. Deborah also speaks with Ravi Parikh, medical director of data and technology applications shared resource at Winship Cancer Institute of Emory University, about a novel AI platform he helped develop to translate clinical trial results to real world populations. News Roundup Phase 2 cancer drug trials Study in the Journal of the National Cancer Institute   Nun Study insights Review article in Alzheimer's & Dementia  DORIAN GRAY project Press release by the European Society of Cardiology Aspirin for preventing cancer spread Study in Nature  New clinical trial map  News announcement on the EMA website Molecule rivaling Ozempic Study in NatureThe Scope of Things podcast explores clinical research and its possibilities, promise, and pitfalls. Clinical Research News senior writer, Deborah Borfitz, welcomes guests who are visionaries closest to the topics, but who can still see past their piece of the puzzle. Focusing on game-changing trends and out-of-the-box operational approaches in the clinical research field, the Scope of Things podcast is your no-nonsense, insider's look at clinical research today.

Send us a textDr. Kilian Kelly, Ph.D. is Chief Executive Officer and Managing Director of Cynata Therapeutics ( https://cynata.com/ ), a stem cell and regenerative medicine company that is known for its proprietary Cymerus platform, for the scalable and consistent production of mesenchymal stem cell (MSC)-based therapies.Unlike traditional MSC therapies that rely on multiple donors, the Cymerus manufacturing process ensures that cells for therapeutic use can be produced in virtually limitless quantities from a single donor – making the opportunities endless and attractive from a manufacturing standpoint. The company has completed Phase I studies for Graft vs Host disease & Diabetic Foot Ulcers and have a number of Phase II, and even have a Phase III clinical trial, in progress.Dr. Kelly has over 20 years' experience in biopharmaceutical research and development, including almost 15 years focused on the development of mesenchymal stem cell (MSC) based therapies. He joined Cynata in March 2014, initially as Vice President, Product Development, then Chief Operating Officer from May 2019, and since July 2023 has been CEO & MD. At Cynata, he has overseen all stages of the development of the Cymerus induced pluripotent stem cell (iPSC)-derived MSC technology, including the first completed clinical trial of any iPSC-derived product worldwide.Dr. Kelly previously held positions at Biota Pharmaceuticals, Mesoblast Limited, Kendle International, Amgen and AstraZeneca. Dr. Kelly holds a Masters in Pharmacy degree from the Robert Gordon University, Aberdeen, a Ph.D. in Pharmaceutical Sciences from Strathclyde University, Glasgow, and he is a Graduate of the Australian Institute of Company Directors (AICD), Melbourne. He is a member of the International Society for Cell and Gene Therapy (ISCT), the International Society for Stem Cell Research (ISSCR), the Royal Pharmaceutical Society and the AICD.Dr. Kelly also serves on the ISCT Asia-Pacific Industry Committee, the ISSCR Best Practices Working Group for the Development of PSC-Derived Therapies and the Industry Interface Committee of the Center for Commercialization of Regenerative Medicine (CCRM) Australia.#KilianKelly #CynataTherapeutics #InducedPluripotentStemCells #MesenchymalStemCells #Immunomodulation #Immunoregulation #Mesenchymoangioblasts #GraftVersusHostDisease #GVHD #MSC #iPSC #IschaemicHeartDisease #Osteoarthritis #AcuteRespiratoryDistressSyndrome #ARDS #Inflammation #Secretome #Paracrine #RegenerativeMedicine #DiabeticWounds #KidneyTransplantation #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

Jamie is a 62-year-old female who is referred to outpatient cardiac rehabilitation 3 weeks after a myocardial infarction. She reports feeling fatigued with moderate exertion but denies chest pain. Her resting vitals are HR 80 bpm, BP 128/82 mmHg, and SpO₂ 98%. She completed Phase I rehabilitation without complications and is eager to begin exercising to improve her endurance. Which activity is MOST appropriate to initiate during Phase II of cardiac rehabilitation?A) Jogging on a treadmill at 70% maximum heart ratB) Cycling on a stationary bike at 3-5 METsC) Strength training at 50% of 1-rep maxD) Stretching and light walking onlyDOWNLOAD THIS EPISODES CHEATSHEET:www.nptecheatsheet.com/cardiac-rehab1

Erik Wetterling, Founder and Editor of The Hedgeless Horseman website, joins us to discuss the attractive value proposition he sees in 3 different gold – copper – critical minerals junior resource stocks. These companies have all released important exploration news over the last week, which sets up future news releases to build upon their current work programs.   Inflection Resources Ltd. (CSE: AUCU / OTCQB: AUCUF) announced on March 25th that AngloGold Ashanti Australia Limited (NYSE: AU / JSE: ANG) has completed Phase I of the Exploration Earn-in Agreement announced on June 14, 2023 by investing AUD$10,000,000 in the Company's portfolio of copper-gold projects in New South Wales, Australia.  AngloGold Ashanti has designated a total of four copper-gold, Duck Creek, Trangie, Crooked Creek and Nynganto, proceed to Phase II of the Earn-In Agreement.   Magna Mining Inc. (TSXV: NICU) (OTCQB: MGMNF) announced on March 31st a batch of assay results from the producing McCreedy West Mine and the adjacent Levack Mine. Drilling at McCreedy West was focused on the 700 Footwall Cu-PGE zone resource expansion and definition in support of mid-term production planning, and targeted areas near historical mining. Drilling at Levack was targeting the near surface Keel Footwall Cu zone.   District Metals Corp. (TSXV: DMX) (Nasdaq First North: DMXSE SDB) (OTCQB: DMXCF) announced on March 26th drill assay results for five drill holes (GRAGR-151 to -155) completed during the Fall 2024 drill program at the base metal polymetallic Stollberg Property located in the Bergslagen Mining District in south-central Sweden.   * In full disclosure, the companies mentioned by Erik in this interview, are positions held in his personal portfolio, and also may be site sponsors of The Hedgeless Horseman website at the time of this recording.  Additionally, Shad holds a position in Magna Mining at the time of this recording.   Click here to visit Erik's site – The Hedgeless Horseman  

It's public space night, and the wide ranging group discussion ensues. Grant joins Tore for the evening. Bringing people along slowly takes a strategy. Credible information can be fed to soft prime the world. It's disclosure, but a gentle one. Thru whistle blowers works great. We are actually in Phase II. There's more than one Arc Of The Covenant. Science created one version. Huh? Planet X could raise gravitational havoc. Why would NASA be hinting? Poles have flipped before, but we didn't depend on tech back then. Another Y2K? Pyramids exist all over the world. Advanced ancient tech is a good bait subject. Tesla terrorists could be planted. Bergrum and the contract tracing app. What did Jesus study in the unknown years. Was alchemy on the list? Religion as a whip has been very effective. When two or more gather, that's a church. They hijacked all religions, not just Christianity. How important is your faith to you? Dialing God's number outside the space. Focusing on life's purpose, which is service to others. And, it's reciprocal. The essence of the Koran is actually love. The big question remains, is free will there too? Going to bliss without Netflix. The pyramids might be at the epicenter of what's to come. Love yourself and God, then the rest will come naturally.

Three Star Trek: Phase II stories in review.In the 1970s, there were story concepts for 13 original episodes of Star Trek: Phase II. Twin Cities Trekkies did talk about Phase II in 2024, but it is time to talk about the specific episodes that they did. In this episode of Twin Cities Trekkies, Wes reads the outlines for three Star Trek: Phase II stories: "Tomorrow and the Stars," "Deadlock" and "Cassandra."Any feedback you have can be submitted to the Facebook page (facebook.com/tctrekkiespod), or by emailing them at tctrekkiespodcast@gmail.com. Twin Cities Trekkies is also available on Instagram (instagram.com/twincitiestrekkiespod). Find us on BlueSky!You can also leave us comments via the Spotify version of the episode. Just keep in mind the feedback you may give may be featured in an upcoming episode of this podcast.Twin Cities Trekkies is available on many platforms!

David Fleming speaks with Charles KElly about his newest release, "Phase II," exploring - and challenging - the world of smooth jazz.

David Fleming continues his conversation with Charles Kelly about "Phase II." This cd is being marketed to the world of smooth jazz, and is already charting, though Charles made an active decision with this release to challenge the notion OF smooth jazz. David and Charles spoke at least a bit about each track on the disc, so the conversation was divided into two shows.

CancerNetwork®, in collaboration with The American Society for Transplantation and Cellular Therapy (ASTCT), organized an X Space hosted by Rahul Banerjee, MD, FACP, an assistant Professor in the Clinical Research Division at the Fred Hutchinson Cancer Center in Seattle, Washington, and Shernan Holtan, MD, the chief of Blood and Marrow Transplantation and professor of Medicine at Roswell Park Comprehensive Cancer Center.  The conversation took place during the 2025 Tandem Meeting and highlighted many significant presentations and posters on CAR T-cell therapies and transplantation, Banerjee's and Holtan's respective areas of expertise. The following trials were discussed: LBA1 - Phase II Multicenter Trial of Idecabtagene Vicleucel (Ide-cel) Followed By Lenalidomide Maintenance for Multiple Myeloma Patients with Sub-Optimal Response after an Upfront Autologous Hematopoietic Cell Transplantation: Top Line Results from the BMT CTN 1902 Clinical Trial1 “This [study] is nice because it merges 2 worlds. It's like a tandem—but not really a tandem—because you're not doing 2 transplants back-to-back. You're doing a transplant followed by CAR T-cell therapy,” said Banerjee. Abstract 50 - CAR T Cell Therapy in Early Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium2 “In a relatively small cohort, [investigators] found no difference in 9-month survival whether someone got their [CAR T cells] in second-line therapy vs third-line therapy from a statistical perspective. If you look at the curves, it looks like there is a potential benefit to second-line therapy, but there was not enough statistical power to determine a difference,” said Holtan. Poster 340 - CD83 Expression By Human Breast Cancer Mediates Effective Killing By CAR T3 “If there's a way to do [the therapy] armored and have a paracrine delivered in real time—and not given to the whole body—[so] the patient [would] have all the adverse effects and cytokine release syndrome release on their own…that would be awesome,” stated Banerjee.  Poster 317 - Risk Factors for Immune Effector Cell-Associated Enterocolitis (IEC-colitis) in Patients with Relapsed Myeloma Treated with Ciltacabtagene Autoleucel (cilta-cel)4 “From the best that we can tell, ironically, corticosteroids aren't the fix that we want them to be [for immune effector cell-associated colitis]…We were like ‘Diarrhea, whatever. Let's give some steroids and treat it like gut graft-versus-host-disease,' but these patients [didn't] respond as well [to that],” said Banerjee. Poster 572 - Post-CAR-T Driving Restrictions Appear Unnecessary after Week 4: Data from the US Multiple Myeloma Immunotherapy Consortium5 “Patients and their caregivers [who have] put their life aside for 4 weeks just to get through CAR T-cell therapy and the Risk Evaluation and Mitigation Strategies requirements are now being told ‘You're free to go, but you can't drive for 4 weeks, which means you can't get your own groceries or…go to doctor's appointments by yourself.' Basically, we argue…that this [requirement] is not evidence-based,” stated Banerjee.  Presentation 58 - Physical Function Measures Identify Non-Hodgkin Lymphoma Patients at High Risk of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) and 1-Year Mortality after Chimeric Antigen Receptor T (CAR-T) Cell Therapy6 “This [presentation] highlights that even within a high [CAR-HEMATOTOX group], those patients were at extraordinarily high risk of not benefitting from CAR T-cell therapy, and these tests are so simple to do. It's going to be interesting to see if others can reproduce this,” said Holtan. Poster 618 - Comparison of Outcomes after Hematopoietic STEM Cell Transplantation (HCT) for Myelodysplastic Syndrome (MDS) Patients Older or Younger THAN 65 YEARS Old. a Retrospective Analysis of the Latin America Registry7 “My personal hope for this space is that our field can come up with more novel conditioning regimens such that we can ablate the marrow without causing those gastrointestinal toxicities or other organ toxicities [while] doing that so effectively that we don't even need maintenance therapies for a lot of conditions,” stated Holtan. Presentation 39 - Determinants of Immune Suppression Discontinuation in the Modern Era: A CIBMTR Analysis of 18,642 Subjects8 “I'm going to make a provocative prediction for the next paper [approximately 10 years from now]. I predict that steroids won't be the first-line therapy for acute or chronic graft-versus-host-disease,” Holtan said. Poster 516 - Patient Experiences with Chronic Graft-Versus-Host Disease and Its Treatment in the United States: A Retrospective Social Media Listening Study9 “We can still work together to make life as good as we possibly can [for patients], to improve physical function, to take away some of this mental distress, and then work together for advocacy too. [We can] help with peer support, help with resources, and help relieve some of that misunderstanding in the community,” stated Holtan. References 1.        Garfall AL, Pasquini MC, Bai L, et al. Phase II multicenter trial of idecabtagene vicleucel (ide-cel) followed by lenalidomide maintenance for multiple myeloma patients with sub-optimal response after an upfront autologous hematopoietic cell transplantation: top line results from the BMT CTN 1902 clinical trial. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Abstract LBA-1. 2.        Rojek AE, Ahmed N, Gomez-Llobell M, et al. CAR T cell therapy in early relapsed/refractory large B-cell lymphoma: real world analysis from the cell therapy consortium. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Abstract 50. 3.        Betts BC, Davilla ML, Linden AM, et al. CD83 expression by human breast cancer mediates effective killing by CAR T. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Poster ID 340. 4.        Chang Lim KJ, Chhabra S, Corraes ADMS, et al. Risk factors for immune effector cell-associated enterocolitis (IEC-colitis) in patients with relapsed myeloma treated with ciltacabtagene autoleucel (cilta-cel). Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Poster ID 317. 5.        Banerjee R, Richards A, Khouri J, et al. Post-CAR-T driving restrictions appear unnecessary after week 4: data from the US multiple myeloma immunotherapy consortium. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Poster ID 572. 6.        Herr M, McCarthy P, Jacobsen H, et al. Physical function measures identify non-Hodgkin lymphoma patients at high risk of immune effector cell-associated neurotoxicity syndrome (ICANS) and 1-year mortality after chimeric antigen receptor T (CAR-T) cell therapy. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Presentation ID 58. 7.        Duarte FB, Garcia YDO, Funke VAM, et al. Comparison of outcomes after hematopoietic STEM cell transplantation (HCT) for myelodysplastic syndrome (MDS) patients older or younger THAN 65 YEARS Old. A retrospective analysis of the Latin America registry. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Poster ID 618. 8.        Pidala J, DeFlilipp Z, DeVos J, et al. Determinants of immune suppression discontinuation in the modern era: a CIBMTR analysis of 18,642 subjects. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Presentation ID 39. 9.        Cowden M, Derrien-Connors C, Holtan S, et al. Patient experiences with chronic graft-versus-host disease and its treatment in the United States: A retrospective social media listening study. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Poster ID 516.

A breaking news podcast from ASCO GU in San Francisco! Prof Louise Emmett (St Vincent's, Sydney), has just read out the latest update from the ENZA-P trial (and simultaneous publication in Lancet Oncology), reporting that the combination of LuPSMA and enzalutamide improves overall survival when compared with enzalutamide alone, in men with poor prognosis mCRPC. Big news!! A 45% reduction in the risk of death in favour of the combination. Plus excellent quality of life for those receiving the combo. We are joined by Louise and co-author A/Prof Andrew Weickhardt (Austin Health, Melbourne), to discuss this exciting data from the ENZA-P trial, and what it means for the future of not just mCRPC, but also for similar combinations in mHSPC.ENZA-P is an investigator-initiated Phase II trial led by ANZUP in partnership with the Prostate Cancer Research Alliance, a join initiative between the Australian Government and Movember. Your co-hosts as ever are Professor Declan Murphy and Dr Renu Eapen. This is a Themed podcast supported by our Gold Partners, Astellas, and our Silver Partners, Novartis. Even better on our YouTube channelLinks:Lancet Oncology paperANZUP 

Sulfurophane and health - It is clear now that SFN stands out as a powerhouse phytochemical with profound effects on human health through the pathway of nurclear factor erythroid related 2 (NRF2). It is found abundantly in cruciferous vegetables such as broccoli, broccolini, kale, and brussels sprouts. SFN is a bioactive compound with impressive clinical potential for preventing chronic disease and optimizing cellular health, especially in oxidant impaired/overloaded states. At its core, SFN is a sulfur-rich molecule derived from glucoraphanin, a glucosinolate precursor. The transformation occurs when the enzyme myrosinase, released during the chopping or chewing of cruciferous vegetables, catalyzes the reaction. Interestingly, this enzymatic activation can also be achieved via gut microbiota when raw vegetables are absent from the diet, emphasizing the remarkable adaptability of our biology to source essential nutrients as needed for survival. (Ali et. al. 2023) Nrf2 is a master regulator of cellular defense, orchestrating the production of detoxification enzymes, antioxidants, and other cytoprotective proteins. By activating Nrf2, sulforaphane enhances the body's resilience to oxidative stress, a key contributor to aging, inflammation, and the development of chronic diseases such as cardiovascular disease and diabetes. Studies reveal that sulforaphane also induces Phase II detoxification enzymes, such as glutathione S-transferase, which play a vital role in neutralizing and excreting harmful toxins.

The Biden administration released anticipated guidance Wednesday for federal agencies to implement the OPEN Government Data Act and reupped the Chief Data Officers Council after it lapsed last month, completing two key actions for federal data pol icy. Under the Office of Management and Budget memo (M-25-05), commonly known as “Phase II” guidance, agencies have long-awaited marching orders on how to create and maintain comprehensive data inventories and make their data open by default. That includes requirements to create a data inventory that is interoperable with the Federal Data Catalog, conform to the metadata schema approved by the White House, and publish that inventory on the agency's website. The memo reestablishing the CDO Council (M-25-06), meanwhile, gives the panel the ability to start exactly how it left off when its authorization lapsed Dec. 15 with the same membership and leadership. That will be important for carrying out the work under the Phase II guidance as the CDO Council is partly responsible for one of the first actions. That cybersecurity executive order we mentioned earlier in the week is officially here. President Biden on Thursday issued the EO on Strengthening and Promoting Innovation in the Nation's Cybersecurity, ordering additional actions to improve the nation's cybersecurity, focusing on defending digital infrastructure, securing the services and capabilities most vital to the digital domain, and building capability to address key threats, including those from the People's Republic of China. The order constitutes one big last stab at cybersecurity in the Biden administration's 11th hour and is a follow-up to an order published in the first year of his presidency. It gives agencies 53 deadlines, stretching in length from 30 days to three years. The Daily Scoop Podcast is available every Monday-Friday afternoon. If you want to hear more of the latest from Washington, subscribe to The Daily Scoop Podcast  on Apple Podcasts, Soundcloud, Spotify and YouTube.

Happy New Year! BioSpace released our NextGen: Class of 2025 this week, highlighting 25 biopharma startups to watch this year. The companies on this list are not afraid of a challenge, wading into some of biopharma's most competitive therapeutic spaces. As analysts predict an uptick in M&A in '25, could some of them be potential targets? One NextGen 2025 company that could already be fielding calls is Metsera, which reported promising Phase II data for its investigational subcutaneous GLP-1 therapy on Tuesday. The GLP-1 space continues to garner significant attention, with both Eli Lilly and Novo Nordisk seeking to protect their drugs against competition from compounders. This strategy makes a lot of sense as the sizzling class continues to expand into heart disease, sleep apnea and metabolic dysfunction-associated steatohepatitis, among other indications. On the regulatory side, the FDA approved 55 novel medicines in 2024—including a few inaugural company approvals—and is looking ahead to several key PDUFA dates in Q1, 2025. Meanwhile, the agency released three new guidance documents seeking to provide clarity around confirmatory trials supporting accelerated approvals, the use of AI in drug development and the use of tissue biopsies in clinical trials. Finally, BioSpace senior editor Annalee Armstrong heads to the J.P. Morgan Healthcare Conference next week as biopharma seeks an M&A spark to improve the currently a gloomy sentiment. Stay with us for all the biggest news coming out of JPM.

A JAMA study identified factors linked to loss to follow-up in diabetic retinopathy and macular edema patients, including male gender, distance from care, and sociodemographic disparities. In Vietnam, six months of levofloxacin therapy showed a non-significant reduction in multidrug-resistant tuberculosis, emphasizing the balance between benefits and tolerability. Finally, Phase II trial showed pancigromab's promise in addressing cancer cachexia, with weight gain and symptom improvement, supporting further research.

With most of the highly attractive late-stage assets already scooped up, pharmas are turning their sights to Phase II companies, and lining up their case to make an attractive offer and move fast. About 40% of the M&A deals in 2023-24 were completed in less than six weeks, from approach to announcement, according to Lazard's data. Michael Kingston and Dale Raine, global co-heads of biopharma at Lazard, joined The BioCentury Show this week to discuss the M&A outlook amid the still-precarious biotech financing landscape.The BioCentury Show, featuring BioCentury one-on-one with an industry KOL, is available on Apple, Spotify and wherever you listen to your favorite podcasts and in video podcast format on BioCentury's YouTube channel.View full story: https://www.biocentury.com/article/65385800:00 - Introduction03:01 - Capital Markets Outlook06:01 - M&A15:19 - Breaking Down Deals24:29 - AsiaTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Vertex Pharmaceuticals experienced a 13% decrease in its share price following the disappointing results of its non-opioid pain therapy, suzetrigine, in a Phase II trial. Meanwhile, major players like Bayer, Bristol Myers Squibb, and Johnson & Johnson announced significant layoffs, impacting hundreds or even thousands of employees. Roche also faced setbacks as their Parkinson's drug failed to meet expectations in a mid-stage trial. Novartis made the decision to cut jobs in both Boston and Munich, while Mesoblast celebrated FDA approval for a mesenchymal stromal cell therapy for GVHD.On a more positive note, the FDA confirmed that there is no shortage of Lilly's GLP-1s and provided compounding pharmacies with a grace period before implementing new regulations to halt their production. Intelligencia AI's accurate pre-ASH predictions for high-potential biotechs demonstrated the efficacy of its predictive AI methodology. Amidst these challenges and changes, the biopharma industry is navigating evolving market dynamics and making strategic decisions to adapt to the shifting landscape.

HEALTH NEWS   ·         Mediterranean plants show promise for cardiovascular disease treatment ·         Walking away from depression: How daily steps improve mental health ·         Phase II trial finds fish oil reduces prostate cancer progression in men undergoing active surveillance  ·         Hot tub therapy offers hope for people with type 2 diabetes ·          Study: Sugary Drinks Increase Risk of Endometrial Cancer in Women ·         Transcendental Meditation most effective at treating PTSD in largest review to date 

[SEGMENT 2-1] Great Days for America 1 All the people behind the targeting of Trump will exposed in the coming weeks. They will all either accept pleas or be made to face justice. We have 4 years to correct the horrible wrongs faced by this great nation during the era of Biden, and era of politics replete with corruption and debauchery. Time made President Trump: Man of the Year. Not that he needed their endorsement.  [SEGMENT 2-2] Great Days for America 2 Trump went from pariah to GOAT. He's a HERO He went from quicksand under his feet to a firm foundation I don't know many presidents who go into office with this type of mandate, and I don't mean what we've conjured up in our minds as MAGA. Americans are overjoyed about Trump's return.   First president to ring the bell at the NYSE since 1985 when they chose Reagan. Trump's name will last as long as Reagan's in the lexicon of political discussions and particularly admiration by Conservatives.   The resignation of Christopher Wray is a great day for America as it will end the Weaponization of what has become known as the United States Department of Injustice. I just don't know what happened to him. We will now restore the Rule of Law for all Americans. Under the leadership of Christopher Wray, the FBI illegally raided my home, without cause, worked diligently on illegally impeaching and indicting me, and has done everything else to interfere with the success and future of America. They have used their vast powers to threaten and destroy many innocent Americans, some of which will never be able to recover from what has been done to them. Kash Patel is the most qualified Nominee to lead the FBI in the Agency's History, and is committed to helping ensure that Law, Order, and Justice will be brought back to our Country again, and soon. As everyone knows, I have great respect for the rank-and-file of the FBI, and they have great respect for me. They want to see these changes every bit as much as I do but, more importantly, the American People are demanding a strong, but fair, System of Justice. We want our FBI back, and that will now happen. I look forward to Kash Patel's confirmation, so that the process of Making the FBI Great Again can begin. Thank you   There is ONE reason why Fani Willis refuses to turn over her communications on J6. She's guilty and so are they. She has been INSTRUCTED not to turn this information over.  [SEGMENT 2-3] Great Days are Coming 3 – Pardons   Chris Wray's legacy will be turning the world's most powerful law enforcement agency into a domestic terror operation that includes raiding the home of the former president, entrapping individuals into politically-oriented hoaxes like Whitmer fednapping, colluding with Big Tech to protect the Biden crime family by censoring Americans, and using the FBI counterterrorism task force to investigate, raid, and arrest nearly 1,600 Americans who protested the 2020 election on January 6. His failures include record crime, a bleeding southern border, out of control fentanyl crisis, and historic low trust in the FBI. Seems impossible but the worst FBI director in US history. The damage he caused this country may never be fully repaired. WTF?! Joe Biden just pardoned multiple Chinese spies and an individual convicted of possessing child p*rnography   https://www.ft.com/content/3378545d-d1bc-4fe6-880c-69ff5c649a05 Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.com T&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found here. https://www.ft.com/content/3378545d-d1bc-4fe6-880c-69ff5c649a05China has hailed the release by the US of three Chinese citizens including an allegedly politically connected former student convicted of possessing child pornography. Jin Shanlin was freed as part of a rare prisoner swap negotiated with the Biden administration that China's foreign ministry said on Thursday was the result of “tireless” government efforts. While the other two Chinese citizens were imprisoned in the US on espionage-related convictions, Jin pleaded guilty in 2021 to possessing child pornography. During his trial in Texas, an FBI special agent testified that his family was “connected to influential members of the Communist party in China”, according to court records. China's foreign ministry said on Thursday its three citizens had been wrongfully detained by the US and were safely returned home through the “tireless efforts of the Chinese government”.  “This once again demonstrates that China will never abandon its compatriots under any circumstances, and the motherland will always be their strong support,” said foreign ministry spokesperson Mao Ning.  Jin, 26, had admitted possessing and distributing “more than 600 images and videos of child pornography” while he was studying for a PhD at Southern Methodist University in Texas.  Local police department investigators said an internet protocol address linked to Jin's residence had used a peer-to-peer network to share a video of “sexual assault of an infant by an adult male” along with other child porn.  Police said they found child pornography open on Jin's computer when they entered his home, which included “videos involving infants and toddlers”.     https://deepnewz.com/china/biden-grants-clemency-to-chinese-national-convicted-child-pornography-espionage-4efaf070 I asked for a comedic take on Biden's massive pardon spree, and particularly on this article where he pardoned Chinese nationals. [START] https://deepnewz.com/china/biden-grants-clemency-to-chinese-national-convicted-child-pornography-espionage-4efaf070 President Joe Biden has granted clemency to Shanlin Jin, a Chinese national convicted of possessing 47,000 images of child pornography. Yanjun Xu, a Chinese spy sentenced to 20 years for espionage. Jin had served four years of his 97-month sentence after pleading guilty. The Plano police confirmed 1,338 images and videos on Jin's computer, including infant sexual assault. For additional context, here is another article that references the deal: https://www.ft.com/content/3378545d-d1bc-4fe6-880c-69ff5c649a05 Was HUNTER on there? Xu was convicted for plotting to steal proprietary information from aviation companies, including GE Aviation. The decision to grant clemency to these individuals has sparked significant controversy and criticism. [END] The only people discussing this are Conservatives. Interestingly, if you Google "Biden pardons", the information on the pardon of the Chinese won't come up. You must dig really deep or go to X to find the link mentioned above. It's as if the fake news media doesn't want to report about the pardon of the Chinese nationals. Instead of highlighting these pardons, all the other stories highlight Americans who have turned their lives around, and now act as exemplary citizens. Even if you add "Chinese Pardons" to the Google search, no story reveals the pardons to the Chinese. I proposed that Biden pardoned these people at the behest of the Chinese government, because the perpetrators are spies, and Biden was threatened by the Chinese for his potential dealings in China for which he pardoned Hunter in Phase I of his pardons. Phase II is a Pardon-a-Palooza as Biden pardoned over 1,500 people under the guise that they were either sentenced too long for their crimes or other so-called humanitarian reasons. I'm not buying this, at least not for the Chinese pardons. Finally, Phase III is where Biden will go hog wild, as we say in the country. Phases I and II were all to set up what Biden is about to do. He's trying to spread the outrage, because Phase III will be huge, as Biden pardons his remaining family members, and all of the upper echelon of the agencies in the DOJ down to middle-management.    “Joe's Great Pardon Bazaar: Everything Must Go!”“Biden's Backroom Deals: Now with Free Spy Exchanges!”“The Art of the Pardon: Joe Biden Edition”“Pardon Me? The Biden Family Clearance Sale”“From Hard Drives to Hard Time: Biden's Clemency Chronicles”“Keeping Up with the Clemencies”. And the latest episode? Pardon-a-Palooza. Apparently, Joe's handing out pardons like Oprah hands out cars. “You get a pardon! You get a pardon! Everybody gets a pardon!” So, Joe Biden's pardoning spree is in full swing. And it's not like he's just handing out Get Out of Jail Free cards to someone who shoplifted a Snickers. No, we're talking about hardcore criminals. Chinese nationals convicted of espionage and, uh, crimes so heinous that even Jeffrey Epstein would've been like, “Whoa, too far.” A pretty low bar for clemency, eh? “Are you a threat to national security or basic human decency? Congratulations! You qualify!”   Let's Become a supporter of this podcast: https://www.spreaker.com/podcast/the-kevin-jackson-show--2896352/support.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The FDA's accelerated approval pathway, established in 1992, has allowed over 200 new drugs to come to market based on surrogate endpoints. While many products have later received full FDA approval, recent withdrawals like Pfizer's Oxbryta and Takeda's Exkivity have raised concerns about the risks of this pathway. Despite some high-profile failures, the program has a strong track record, with over half of accelerated approvals converting to full approval. The pathway has been used primarily for cancer treatments but is now expanding to other disease areas like neurological and rare diseases. Recent failures of confirmatory trials for drugs like Sarepta's Elevidys have prompted experts to call for tighter timelines and better biomarkers for surrogate endpoints in order to improve the program. The future of the accelerated approval pathway is under scrutiny, with questions arising about how often it should be used and what areas it should focus on next.AbbVie's Tavapadon showed improvement in motor and daily living complications in a Phase III trial, following the failure of another key cerevel asset, Emraclidine. Relmada Therapeutics is considering strategic alternatives, including a potential sale, after halting two Phase III trials for a major depressive disorder drug. Other news includes BioAge discontinuing a Phase II obesity study, Merck's promising anti-ROR1 ADC data for lymphoma treatment, and Novo and Catalent's $16.5 billion deal receiving EU approval. Additionally, Vertex and Beam report advances in SCD cell and gene therapies, while evidence grows for the potential of GLP-1s in Alzheimer's disease.Recent studies have shown that GLP-1 receptor agonists, commonly used for weight loss and diabetes, may have potential in treating Alzheimer's disease. Phase III results from Novo Nordisk are expected next year. Additionally, amylin analogs are emerging as a potential alternative or complement to GLP-1 receptor agonists for weight loss with a cleaner tolerability profile. Other news includes a weight loss victory claimed by Lilly over Novo in a head-to-head study, FDA action alerts, and promising cancer therapies from companies like AstraZeneca and Merus. The FDA is also investigating the safety of Bluebird's gene therapy Skysona for hematologic malignancies. Applied Therapeutics recently faced a crash after FDA rejection of a rare disease drug. Overall, the potential of GLP-1s in Alzheimer's disease and the emergence of amylin analogs in weight loss are significant developments in the biopharma industry.

2025 Industrial Insiders Registration NOW OPEN! https://industrialize.com/membership Following Pat 1 of this interview I had many more questions to ask Jim. Join in as we do a deep dive into phase II's! About Jim: Jim is a familiar voice in commercial real estate consulting, advising clients for over 25 years on environmental and property condition due diligence, asset management, construction project management, ADA/accessibility, and policy/training programs. He chairs ASTM International's Subcommittee E50.02 on Real Estate Assessment and Management and leads ASTM task groups on Phase-I ESAs (E1527), Limited Moisture Assessments (E3026); Drone Assessments of Commercial Real Estate (WK86230), and Facility Condition Assessments (WK92482). Connect with Jim: LinkedIn: https://www.linkedin.com/in/jamesebartlett Bureau Veritas website: www.bvna.com ASTM website: https://www.astm.org/ --

In this episode, we delve into the art of detoxification, focusing on two key areas: sleep and liver health. We'll also introduce Liver Boost, a supplement designed to support your liver's detoxification processes. Join us as we unravel the secrets of effective detox and discover how Liver Boost can enhance your journey to wellness.   Show Notes: Improving Sleep for Effective Detox: Understanding the metabolic dysregulation caused by sleep issues[^1^]. The antioxidant role of melatonin in detoxification[^3^]. Genetic factors influencing sleep and the role of melatonin supplementation[^2^]. Studies: PMC on Sleep and Metabolism: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2929498/ PMC on Genetic Influences on Sleep: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8974368/ PubMed on Melatonin: @8/ Supporting Liver Detoxification (Phase I & II): The role of xenobiotic biotransforming enzymes in liver detox[^1^]. Phase I detoxification involving the cytochrome P450 enzymes[^1^]. Personalized dietary considerations for optimizing liver detoxification[^1^]. Crucial foods for Phase II detoxification[^1^]. Study: PubMed on Liver Detoxification: https://pubmed.ncbi.nlm.nih.gov/1749210/ Foods to Support Detox Organs: Nrf2/GST/Sulfurnarse supportive foods like curcumin, green tea, and garlic. Cruciferous vegetables, citrus fruits, and specific beverages beneficial for liver health[^1^].   Study: PMC on Foods and Liver Detox: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4488002/ Acute Exposure Detox with NAC (Liver Boost): The importance of N-acetyl cysteine (NAC) in increasing GST for liver detox[^1^][^2^]. Dietary sources to support methylation and Nrf2 activation[^2^].   Studies: PMC on NAC and Liver Health: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4488002/ PMC on GSH and Metabolism: @icles/PMC3464379/ MTHFR Issues Hindering Detox: The impact of MTHFR polymorphisms on detoxification processes[^1^][^2^]. Importance of nutrient cofactors and methyl donors in managing MTHFR issues[^1^]. Studies: PMC on MTHFR and Detox: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4488002/ PMC on MTHFR Polymorphisms: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8703276/   Remember that effective detoxification is crucial for overall health. To support your liver's natural detoxification processes, consider adding Liver Boost to your regimen. Formulated to enhance Phase I and II liver detoxification, Liver Boost can be your ally in achieving optimal health and vitality. Click https://www.mswnutrition.com/products/liver-love/?ref=nursedoza  to embark on a journey towards a cleaner, more energized you.

KB is BACK and kicks things off celebrating another Victory Monday for the Eagles as they take down the Rams in LA on Sunday Night Football. He discusses Saquon Barkley's UNREAL and historic performance that helped propel the team to victory. He also discusses the unfortunate news that Brandon Graham tore his triceps and is out for the remainder of the season. KB discusses BG and his importance to the franchise and why the Eagles gotta go and win it all for BG now. Then he discusses the Sixers continuing to stink, the Flyers grinding out a win this weekend against Chicago and Matvei Michkov is unreal. He also touches on Juan Soto SZN advancing to Phase II and gives some fun news happening this week at Underground! GO BIRDS! Onboarding Form: forms.gle/mZYnkiQcGv1ZxBSg9 Voicemail Line: speakpipe.com/UndergroundSportsPhiladelphia Support Our Sponsors! The City of Vineland: Visit www.vinelandcity.org/ and stay connected with the community and learn about important announcements, programs, and services offered by the city! Vineland, New Jersey... Where It's Always Growing Season! '47 Brand Shop for your favorite sports fan and get 30% off SITE WIDE from Black Friday through Cyber Monday and get FREE SHIPPING on ALL orders with '47 Brand! 47.sjv.io/GmAQ2k Kenwood Beer Visit kenwoodbeer.com/#finder to see who has Kenwood Beer on tap in your area! (MUST be 21+ to do so and PLEASE drink responsibly.) Paramount+ Sign up for Paramount+ and stream the NFL all season long! https://paramountplus.qflm.net/c/2698521/2140293/3065 FOCO Shop the new, officially licensed 76ers merchandise & collectibles from FOCO! linktr.ee/undergroundsportspartnerships Merch & Apparel: www.phiapparel.co/shop + Use Code "UNDERGROUND" for 10% off! Duracell Portable Power Stations For a limited time - Take 35% off Sitewide Plus Free Shipping. Use code CYBER35 linktr.ee/undergroundsportspartnerships Tomahawk Shades Take 25% off your next order with code USP at tomahawkshades.com or in the Tomahawk Shades App! Follow Us! Twitter: twitter.com/UndergroundPHI Instagram: www.instagram.com/undergroundphi/ TikTok: tiktok.com/@undergroundphi KB: twitter.com/KBizzl311 Watch LIVE: YouTube: www.youtube.com/@UndergroundSportsPhiladelphia FB: facebook.com/UndergroundSportsPHI Twitch: twitch.tv/UndergroundsportsPHI Intro Music: Arkells "People's Champ" Outro Music: Arkells "People's Champ" #subscribe #Eagles #FlyEaglesFly #Phillies #Sixers #Flyers #fyp

Dr. Lisa Pomeroy is a traditional naturopath with extensive training in functional medicine, lab test interpretation, and gut microbiome balancing through the Kalish Institute, The Microbiome Restoration Center, Functional Diagnostic Nutrition (FDN), and other organizations. In addition to being a graduate of the Kalish Institute Mentorship Program, Lisa is a Certified Microbiome Analyst through Dr. Jason Hawrelak. Currently, she works as a clinical consultant for Diagnostic Solutions Laboratory, and educates health practitioners on functional lab test interpretation through her business Pomeroy Institute For Functional Nutrition. In this episode, Dr. Pomeroy talks about the differences in the various gut health tests, how GI-MAP test compares to other tests and what some of the insights the DUTCH test can provide are. Learn more about Dr. Pomeroy and her training courses for health practitioners on Interpreting the GI-MAP Test and Interpreting the DUTCH Test here: https://www.pomeroyinstitute.com/ Get 15% off Peluva minimalist shoe with coupon code COACHTARA here: https://peluva.com/ CHAPTERS: 0:00 Intro 4:05 What the DUTCH test is 8:23 Phase II estrogen metabolism 12:13 Dr. Lisa's gut health background 17:30 Brain fog and gut health connection 20:20 Migraines 22:35 Mucosa lining 25:10 SIBO 28:57 Gut health testing 36:11 Gut health & hormones

It's too soon to conclude anti-amyloid therapies are safe for use by Alzheimer's patients in the real world, even as early reports are encouraging, argues BioCentury Executive Editor Selina Koch on the latest BioCentury This Week podcast. Koch and colleagues discuss takeaways from this year's Clinical Trials on Alzheimer's Disease annual meeting, including conclusions from adverse event data for Leqembi lecanemab and what the true test of appropriate use and safety for the drug might look like.BioCentury's editors also assess Phase II data presented at CTAD by UCB that provide some of the first clues about what species of tau to target and in which patients. And they discuss what results of Tuesday's presidential contest in the U.S. will mean for FDA, as well as the state of play for China biotech as the industry continues to grind out its first bear market.View full story: https://www.biocentury.com/article/65407500:00 - Introduction01:23 - CTAD: Anti-amyloids14:22 - CTAD: UCB's tau data19:47 - FDA & the Election28:16 - China Summit DebriefTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Watch The X22 Report On Video No videos found Click On Picture To See Larger PictureMore and more banks are being investigated for money laundering, they said criminals only use bitcoin for money laundering. US economy grew because of gov spending and inflation. Fed cuts rates mortgage rates climb higher. As the economy implodes gold and bitcoin will skyrocket. The [DS] is trying everything they can to manipulate the election using ballots. The problem is that the people continue to catch them cheating, which is making hard for the [DS]. Dominion machines have been affected nationwide and might not produce the right results. The honeypot that Comey used on Trump has been exposed. The [DS] is panicking, its all falling apart on them.   (function(w,d,s,i){w.ldAdInit=w.ldAdInit||[];w.ldAdInit.push({slot:13499335648425062,size:[0, 0],id:"ld-7164-1323"});if(!d.getElementById(i)){var j=d.createElement(s),p=d.getElementsByTagName(s)[0];j.async=true;j.src="//cdn2.customads.co/_js/ajs.js";j.id=i;p.parentNode.insertBefore(j,p);}})(window,document,"script","ld-ajs"); Economy BofA Warns "Enforcement Action" By Feds Possible Over Money Laundering, Zelle  A little more than two weeks after Toronto-Dominion Bank pleaded guilty to multiple criminal charges and paid $3 billion in fines and other penalties to the Department of Justice and financial regulators for failing to monitor money laundering operatio  the Corporation's Bank Secrecy Act/anti-money laundering and sanctions compliance programs (Programs), including transaction monitoring, training, governance, and customer due diligence."  "In cooperation with regulators, the Corporation has been, and plans to continue, implementing enhancements to these Programs. The Corporation is continuing discussions with its regulators about the Programs, and resolution of these discussions may include one or more public orders by the regulators," BofA continued. BofA is responding to an inquiry from the Consumer Financial Protection Bureau into electronic payments on the Zelle payment network. "The CFPB staff has initiated discussions with the Corporation to pursue a resolution of the inquiry or file an enforcement action. The Corporation is evaluating next steps, including litigation," the bank said. The filing did not mention specifics about potential AML issues. However, the TD Bank case, where the Canadian bank chose profits over AML compliance, allowed fentanyl and narcotics trafficking operations to use banking services. Source: zerohedge.com U.S. Economy Grew At 2.8% Pace In Third Quarter The U.S. economy expanded at a 2.8 percent annual pace in the third quarter, the Commerce Department said Wednesday. Consumer spending jumped  3.7 percent in the third quarter, the largest rise in six quarters. That was much higher than the three percent expected. Imports, which are a subtraction from GDP, soared in the third quarter. Imports of goods climbed 11.6 percent, partially reflecting U.S. importers pulling forward imports for fear that the port worker strike would be a lasting obstacle to bringing in foreign-made products. This dragged down GDP by nine-tenths of a percentage point. Government spending was a big source of economic growth in the quarter, adding nine-tenths of a percentage point to GDP growth. Source: breitbart.com https://twitter.com/KobeissiLetter/status/1851291535683318037  for $420,400 which means a mortgage payment with 20% down would be $2,343/month. Including taxes and insurance, homebuyers can now expect to spend over $3,000/month. In other words, homebuyers are now spending over 50% of their post-tax income on home payments. Truly mind-blowing numbers. https://twitter.com/KobeissiLetter/status/1851659293059141954    $3,000 monthly budget can now afford a $442,500 home, down from $475,750 on September 17th, the lowest since February 2023. A homebuyer with a $2,

Watch The X22 Report On Video No videos found Click On Picture To See Larger PictureThe oil companies are now shifting away from the green agenda, they are realizing that if they continue down this path they will go bankrupt. [KH] plan is the same plan the [DS] has been pushing, tax the rich. Gold bars at Costco are flying off the shelf, why would that be if the economy is strong. The [DS] is in trouble, [KH] fake poll numbers are imploding, they will not have the poll numbers to create the ballots they need. [DS] ready to shift into Phase II of the election rigging. They need to give [KH] a boost or they need to swap her out. The [DS] ready to move into phase II which is post election. The stage has been set and now the [DS] is going down the path the patriots have set for them.   (function(w,d,s,i){w.ldAdInit=w.ldAdInit||[];w.ldAdInit.push({slot:13499335648425062,size:[0, 0],id:"ld-7164-1323"});if(!d.getElementById(i)){var j=d.createElement(s),p=d.getElementsByTagName(s)[0];j.async=true;j.src="//cdn2.customads.co/_js/ajs.js";j.id=i;p.parentNode.insertBefore(j,p);}})(window,document,"script","ld-ajs"); Economy Energy Giant Puts Goal To Drastically Cut Oil, Gas Production On Ice European energy company BP has abandoned its pledge to cut oil and gas production by 2030 as the firm aims to shore up investor confidence amid a slide in its share price, Reuters reported Monday. BP unveiled plans in August 2020 to reduce its oil and gas output 40% by 2030, before dialing back the target to 25% in February 2023, according to Reuters. Now, in an attempt to regain the trust of investors, CEO Murray Auchincloss has dropped the target altogether in what sources told Reuters is part of a broader corporate strategy shift to focus on profitability and returns rather than green initiatives The news follows BP announcing plans to sell its roughly $2 billion U.S. onshore wind portfolio in September and comes as the company's share price sits at a near two-year low. It also coincides with a strategy shift at rival energy company Shell, which rejected further cuts to oil production in June 2023 shortly before its CEO Wael Sawan described lowering oil output as “dangerous and irresponsible” in a July 2023 interview with the BBC. Source: dailycaller.com https://twitter.com/Bubblebathgirl/status/1843275996008714598 TAKE A LISTEN https://twitter.com/GRDecter/status/1843303350751949214   https://twitter.com/KobeissiLetter/status/1843306086532788267 https://twitter.com/GRDecter/status/1843266608392732990   Political/Rights https://twitter.com/TheStormRedux/status/1843261819814592887 having a hard time telling the difference between fact and fiction, is creating an impedance to our ability to actually get people the help they need.” She's talking about President Trump, btw. Oh and then Morning Joe chimes in and suggests it could be “foreign powers” Man, these people are toast. https://twitter.com/ThomTillis/status/1843302920084976027   FEMA Abandons Devastated NC Town Residents — ‘Nobody's Been Bringing in Supplies Except Civilians' After Agency Refuses to Drive Around ‘Road Closed' Sign    Chelsea Atkins, 38, a health researcher originally from Buffalo, NY, shared her frustration with FEMA's incompetence in an interview with the New York Post. “FEMA called me and told me they wanted to inspect my house, then called me back to say they couldn't drive around the ‘road closed' sign. They weren't allowed,” she told The Post. “You can drive it by car for sure, it's not that bad, you just have to drive around the ‘road closed' sign. I explained that to them. They said they couldn't.” Take note that it is the very same road The Post successfully traversed on its way to Bat Cave. “FEMA hasn't been here,” Atkins said, adding, “It's been a civilian-run operation since day one.

In this episode, Joe interviews Ingmar Gorman, Ph.D.: clinical psychologist and co-founder and CEO of Fluence, a psychedelic education company. Gorman served as a co-principal investigator and study therapist on MAPS' Phase II and III clinical trials for MDMA-assisted psychotherapy for PTSD, and works with drug sponsors: training, developing the components for clinical trials, and designing therapy manuals. With his insider's perspective, he discusses the reasons why he believes the FDA rejected MDMA-assisted psychotherapy for PTSD: from ICER's 2.1 section of the report giving legitimacy to allegations they don't have the authority to research, to Lykos not being able to defend some accusations due to confidentiality, to the damage caused over time (which likely influenced the decision) from attacks against Lykos from dissenters. He discusses: How, despite abuse claims, the main allegations in the report were actually about the mishandling of data or influence of investigators on participants The complications of needing to follow study frameworks: Should your adverse experience be in the report if it happened outside the study window? How easily opposition can attack and demonize a faceless company, while forgetting the humanity of the people behind it Inner healing intelligence and the proposition that people have been indoctrinated into this concept by MAPS The need for journalists to research more and not just jump on a narrative and more! For links, head to the show notes page. 

Guest host Russ Eagle interviews Clay about Phase II of his 2024 Travels with Charley tour. What has Clay learned from retracing Steinbeck's famous 1960 cross-country journey? This time from Bismarck to Seattle, then Monterey, Salinas, and Route 66. Clay describes a few mishaps that have occurred. Plus, a visit to the Sylvia Beach literary hotel in Oregon, the annual Lewis and Clark Cultural Tour, the magnificence of the American continent, and people's reluctance to discuss our paralytic political situation. Finally, the lingering question: uncovering the best gumbo in America?